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1.1 Spinal cord injury 
1.1.1 Spinal cord anatomy 
The brain and spinal cord are referred to as the central nervous system 
(CNS). The Spinal cord descends down from the brain until the lower back 
and is protected by bony vertebral columns. It is surrounded by a clear fluid 
called, cerebrospinal fluid (CSF). CSF acts like a cushion and protects the 
delicate spinal tissue from damage, which may occur due to banging against 
bony vertebrae. The vertebral column and spinal canal in humans is divided 
into 5 segments, namely 7 cervical (C), 12 thoracic (Th), 5 lumbar (L), 5 
sacral (S) and 1 coccygeal (Co) segments. The Co segment is mainly 
vestigial in humans. In rats the spinal cord is made up of 8 cervical (C), 13 
thoracic (Th), 6 lumbar (L), and 4 sacral (S) and 3 coccygeal (Co) segments. 
The spinal cord is composed of gray and white matter. The gray matter is 
mainly composed of neuronal cell bodies. In the transverse section of the 
spinal cord, the gray matter appears as butterfly or “H”-shaped structure. The 
white matter is composed mainly of axons and glial cells. Generally, a tract is 
defined as a group of nerve fibers of the same origin, course and termination, 
e.g. corticospinal tract (CST), rubrospinal tract (RST). A pathway is defined 
as a group of tracts with functional relation, e.g. motor pathways. The 
pathways carry the information to and from the brain and body organs. Based 
on the information they carry, they are divided into ascending and 
descending pathways. Tracts of the ascending pathway carry sensory 
information such as touch and pain from body organs to the brain, while the 
tracts of descending pathway send the response or modulate the information 
to motor action from brain to other parts of the body (Anderson et al., 2009). 
Figure 1 shows ascending and descending tracts of the rat and human 












Figure 1. Anatomy of the rat and human spinal cord transverse section. 
(a). Comparative cross-section size of the rat and human cervical spinal cord. 
(b). Schematic diagram of the major ascending and descending tracts in the 
rat and human spinal cord. S = sensory tracts; M = motor tracts. Image 
adapted from (Anderson et al., 2009; Silva et al., 2014). 
 
1.1.2 Corticospinal and rubrospinal tracts 
Rodent studies of axonal regeneration and plasticity in the CNS mainly focus 
on two descending motor tracts: the corticospinal tract (CST) and the 
rubrospinal tract (RST). The CST, which is the major motor tract, originates 
from layer V pyramidal cells in the primary sensorimotor cortex. The CST is 
located primarily at the ventromedial base of the dorsal columns in the rat 
spinal cord. CST projections are also seen in dorsolateral white matter and 
also in a small ipsilateral, ventromedial component, which comprises 10–20% 




















in a rat, and mainly control the voluntary, fast and precise paw and finger 
movements, such as grasping for food. A major difference between the rat 
and human spinal cord is the location of the CST. In the rat the CST is 
located in the dorsal white matter, whereas in humans, it is located in the 
lateral white matter (Gemma et al., 1987; Metz and Whishaw, 2002; 
Schwartz et al., 2005). Figure 2 shows the anatomy of the rat CST and RST. 
 
       a                                        b 
 
Figure 2. Anatomy of the rat corticospinal (CST) and rubrospinal tracts 
(RST).  (a) The CST starts at the sensorimotor cortex layer V of the brain and 
runs in the contralateral dorsal and lateral white matter of the spinal cord. (b) 
The RST starts at the red nucleus (RN) of the midbrain and runs in the 
contralateral dorsal and lateral white matter of the spinal cord. SNr = 
substantia nigra pars reticulata; cg = central gray matter; Images (a) and (b) 
were adapted from Paxinos and Watson, 1998; Ruitenberg et al., 2002. 
 
The RST originates from the magnocellular portion of the red nucleus (RN) of 
the midbrain, running through the dorsal lateral white matter of the rat spinal 
cord then through all levels of the spinal cord. The RST terminals are mainly 
distributed in Rexed's laminae V and VI as well as in the dorsal part of lamina 
VII in rat spinal cord (SC). Most rubrospinal axonal projections are found to 
descend contralaterally in the dorsolateral funiculus while few of the 
projections descend in the ipsilateral dorsolateral funiculus. Unlike the CST, 
the RST is entirely confined to the dorsal lateral funiculus of the rat SC and 











This makes the RST an excellent model lesion target for regeneration studies 
with partial lesions. In addition to this, the small size of the RN makes it an 
ideal target for therapeutic proof of concept studies (Blits et al., 2010; Brown, 
1974; Koda et al., 2004; Küchler et al., 2002; Ruitenberg et al., 2002, 2004). 
The RST is a well-defined spinal nerve tract and its function is to control fore 
and hind-limb muscles, over-ground locomotion and skilled movements in 
rats, hence injury to the RST results in functional deficits of the afore 
mentioned limbs and movements (Hendriks et al., 2006; Webb and Muir, 
2003). 
 
1.1.3 Spinal cord lesion and pathophysiology  
Spinal cord injury (SCI) is a devastating and largely irreversible clinical 
condition, which can lead to permanent sensory and motor functional 
disabilities. Worldwide, an estimated 2.5 million people suffer from SCI and 
more than 130,000 new injuries are reported annually (Kundi, 2013; 
Rossignol et al., 2007; Thuret et al., 2006). SCI can be categorized into (1) 
complete SCI leading to none or a few signals passing from the brain to the 
site of injury and, (2) incomplete lesions which, due to partial cut or crush, 
result in an incomplete loss of signals with low chances of partial recovery of 
motor or sensory function over time. Depending on the level of the SCI 
functional deficits and complications vary largely.  
 
The pathophysiology of the human SCI can be described as a two-step 
mechanism, which includes primary and secondary lesions. Primary lesions 
result as a direct damage to the axons, nerve cells and blood vessels, which 
lead the physiological tissue deformation. However, primary lesions trigger 
the activation of several biochemical signalling pathways leading to 
secondary lesion formation (Bunge et al., 1993). The secondary lesion can 
be subdivided into an immediate, acute, intermediate and chronic phase 
(Rowland et al., 2008). The immediate phase (0-2 hrs.) includes transection 
of axons, death of neuronal and glial cells and spinal shock leading to instant 
functional loss in case of complete SCI. Acute axonal degeneration (AAD) 








the axons and haemorrhage in the central grey matter of the SC (Hayes et 
al., 2007; Norenberg et al., 2004; Wang et al., 2012). The events that take 
place during 2 to 48 hours after SCI are categorized as the early acute 
phase. This phase is mainly characterized by several biochemical events 
such as oedema, inflammation, continuous haemorrhage, excitotoxicity, ionic 
dysregulation, free radical production, demyelination, increase in the blood 
brain barrier permeability and apoptotic cell death (Crowe et al., 1997; Emery 
et al., 1998; Mautes et al., 2000; Schnell et al., 1999; Tator and Fehlings, 
1991; Tator and Koyanagi, 1997). From day 2 to the end of week 2 follows 
the subacute phase which shows an active phagocytic response and delayed 
astrocyte activation forming the glial scar, which becomes a barrier for axonal 
regeneration (Donnelly and Popovich, 2008; Hagg and Oudega, 2006). The 
intermediate phase, which lasts for 2 to 6 months, is characterised by a 
continuous development of the glial and fibrous scar with spontaneous 
regenerative axonal sprouting. In the chronic phase (6 months onwards), 
stabilization of the lesion, scar, cyst formation and continuation of Wallerian 
degeneration takes place (Coleman and Perry, 2002; Ehlers, 2004).  
 
Understanding the molecular and cellular events that take place after the SCI 
is important for the development of animal models to target different patho-
physiological phenomena that are specific to each individual phase and to 











Figure 3. Schematic representation of the pathological events after SCI. 
Rapid degeneration of neuronal cell bodies as a result of SCI is accompanied 
by local bleeding at the lesion epicenter further leading to ischemia, 
excitotoxicity, free-radical generation, inflammation, oedema and 
programmed cell death, which contribute to secondary degeneration and 
increase in the lesion core size with time. Elevated levels of collagen and 
chondroitin sulphate proteoglycans (CSPG) by reactive astrocytes contribute 
to scar formation. Image was adapted from Kundi, 2013. 
 
1.2 Axonal regeneration and plasticity after SCI 
The mammalian adult CNS is extremely limited in axonal regeneration. 
However, some limited spontaneous collateral axonal sprouting is observed 
as a compensatory mechanism by the lesioned or spared axons in partial SC 
lesions (Schwab, 1996; Weidner et al., 2001). Axonal sprouts were reported 
within 6 to 48 hours of SCI in mice (Kerschensteiner et al., 2005). In the later 
phases after SCI (2 weeks onwards) spontaneous axonal sprouting was also 
reported, but the extent and duration of the sprouting varies in different spinal 
tracts (Hagg and Oudega, 2006; Hill et al., 2001). However, spontaneous 
axonal sprouting is not sufficient enough to sustain functional recovery and in 
most cases this limited sprouting is aborted due to different inhibitory 









1.3 Barriers of axonal regeneration in the CNS 
1.3.1 Myelin inhibitors 
Research focussing on the repair of the adult CNS had extensively studied 
the intrinsic factors contributing to regenerative failure as well as the 
environment of the lesion. The myelin sheath around the axons, which is 
formed by oligodendrocytes and whose main function is to ensheath the 
healthy axon in order to permit saltatory conductivity, is a rich source of many 
inhibitory molecules. After lesion, severed axons are exposed to various 
myelin-associated inhibitory molecules such as Nogo A, myelin-associated 
glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMGp) (Caroni 
and Schwab 1988; McKerracher, David et al. 1994; Mukhopadhyay, Doherty 
et al. 1994), chondroitin sulfate proteoglycans (Rolls et al., 2009; Yiu and He, 
2006), semaphorins, and ephrins (Benson et al., 2005; Goldshmit et al., 
2004) which act via the activation of the GTPase RhoA. Downstream of 
RhoA, Rho-associated kinase (ROCK) propagates the inhibitory signal and 
thus plays a key role in axonal growth inhibition (Yamashita et al., 2002).  
 
1.3.2 Scar tissue 
In the sub acute and chronic phase of SCI, inflammatory cells are recruited at 
the lesion site and forms a scar. Scar mainly composed of a glial scar 
component and a fibrous scar component. The glial scar in the perilesion 
area consists predominantly of reactive astrocytes, microglia/macrophages, 
extracellular matrix (ECM) molecules and chondroitin sulphate proteoglycans 
(CSPGs) (Yiu and He 2006; Rolls, Shechter et al. 2009). The fibrous scar in 
the lesion core consists rich basement membrane embedded with collagen 
type IV (Shearer and Fawcett, 2001). The lesion scar in the SCI remains to 
be a challenging pathophysiological barrier because of its heterogeneity with 
its both harmful and beneficial properties on axonal regeneration. Most of the 
regeneration failure studies found the axon growth arrest and misrouting of 
axons at the lesion boarder. Studies of axon-astroglial interactions propose 








major axon growth inhibition factor of scar tissue (Fawcett et al., 1989; Frisén 
et al., 1993; Stichel and Müller, 1994; Stichel et al., 1999) 
The long-term goal of SCI research is to institute treatments improving 
axonal regeneration and establishment of neuronal reinnervation by targeting 
those identified barriers of axonal regeneration. Figure 4 illustrates possible 
ways of axonal reinnervation after SCI.                           
 
        a                          b                        c                                    
Figure 4. Scheme of possible axonal reinnervation ways following SCI. 
(a) Long-distance axonal regeneration. Following the SCI, the distal 
segment of the axon undergoes Wallerian degeneration (dotted black lines) 
and new axons (red) sprout from the proximal axonal segment (blue) to 
reestablish synaptic contacts with distal axons. (b) Short-distance growth 
of lesioned axons. Collateral sprouts (red) form synaptic contacts with 
neighboring axons to by-pass the lesion site. (c) Sprouting of spared distal 
axons to maintain synaptic connectivity beyond the injury site. Image was 
adapted from Giger et al., 2010. 
 
1.4 Current treatment approaches for SCI 
Studies in the last 20 years have made an enormous progress in the 
understanding of molecular and cellular pathways that are triggered following 
SCI and provided insights into key mechanisms of tissue damage and 
regeneration failure in the CNS. This basic understanding had led to various 
strategies to repair the SCI and to increase the functional gain. The main 
goals for the SCI research are to improve neuroprotection, increase axonal 
Strategies to reestablish neuronal innervation following injury. 
Giger R J et al. Cold Spring Harb Perspect Biol 
2010;2:a001867 








regeneration and foster functional restitution. To achieve these aims different 
approaches including pharmacological interventions, cell-based therapies, 
tissue engineering with scaffolds and tissue bridges, rehabilitation with 
robotics and target-based therapies for scar and myelin inhibitors have been 
tested in experimental settings. 
 
Cell-based therapies aim to bridge the lesion cyst or cavity with 
neuroprotective or remyelinating cells to create a favorable environment for 
axonal regeneration. Various cell types such as olfactory ensheathing glia, 
Schwann cells and embryonic adult stem cells have been used extensively 
and are tested in ongoing clinical trials (Geffner et al., 2008; Guest et al., 
2013; Knoller et al., 2005; Mackay-Sim et al., 2008). A variety of 
pharmacological agents such as corticosteroids, GM-1 ganglioside (GM-1), 
nimodipine, thyrotropin-releasing hormone (TRH), and naloxone showed 
beneficial effects in preclinical studies of SCI. While their investigated in 
controlled clinical trials have been failed to demonstrate convincing 
neurological benefit due to side effects (James W. Rowland et al., 2008; Silva 
et al., 2014).  
One of the most challenging strategies for SCI treatment is to target major 
obstacles of axonal regeneration: the myelin inhibitors and the scar tissue in 
the CNS. Targeting these obstacles could ameliorate the intrinsic neuro-
protective and axonal regeneration capacity after the lesion. For example, 
anti-scarring treatment with the iron chelator BPY-DCA or chondroitinase 
ABC ameliorated axonal regeneration in vivo (García-Alías et al., 2008; 
Klapka et al., 2005; Schiwy et al., 2009; Starkey et al., 2012; Tester and 
Howland, 2008). Targeting myelin inhibitory molecules such as Nogo-A, MAG 
and downstream effector molecules Rho and ROCK2 improved axonal 
regeneration in various models of spinal cord injury (Buchli and Schwab, 
2005; Dergham et al., 2002; Kastin and Pan, 2005; McKerracher, 2001; 
Rowland et al., 2008). Ongoing clinical trials are thus focused on Nogo 
antibodies and BA-210 (Cethrin(®), which is a Rho inhibitor (Fehlings et al., 









1.5 Anti-scarring treatment (BPY-DCA) 
The structure of the fibrous scar component is impermeable for the regrowth 
of the axons at the lesion site (Fawcett et al., 1989; Frisén et al., 1993; 
Stichel and Müller, 1994; Stichel et al., 1999). In order to create growth 
permissive environment at the lesion site, scar suppression treatments are 
essential. Scar suppression treatments interfering with the synthesis of 
collagen, a supramolecular backbone of the basement membrane structure 
of ECM, were found to be an effective strategy to promote axonal growth at 
the lesion site (Stichel et al., 1999). 2,2’- dipyridine-5, 5’-dicarboxylic acid 
(BPY-DCA) is an iron chelator that inhibits prolyl-4-hydroxylase, a key 
enzyme of collagen biosynthesis. Previous studies of anti-scarring treatment 
with BPY-DCA in combination with 8-bromo-cyclic adenosine 
monophosphate (8-Br-cAMP) have proven beneficial effects on fibrous 
scarring and also improved axonal regeneration in a rat spinal cord lesion 
model (Klapka, Hermanns et al. 2005; Schiwy, Brazda et al. 2009). 
 
1.6 Gene therapy 
A crucial question in SCI treatment is the delivery of target cell specific 
therapeutics to modulate the specific pathways activated after injury. The 
principle of gene therapy is to use DNA as a drug to express the therapeutic 
genes in the target cell via a safe vector system. Viral vectors are the efficient 
tools that could deliver long-lasting cell-specific expression of the therapeutic 
genes. Adeno-associated viruses (AAV) are small (25 nm in diameter) 
dependoviruses from the Parvoviridae family. They could replicate only in the 
presence of a helper virus (either adenovirus or herpes virus). The ability of 
these viruses to infect dividing and non-dividing cells with stable expression 
makes them attractive tools for gene therapy (Buller et al., 1981; Daya and 
Berns, 2008). Recombinant AAV production generates AAV vectors free of 
helper viral genome while keeping the inverted terminal repeats (ITRs), which 
are necessary for transgene cassette expression. Because of the lack of viral 
genome especially the “rep” gene, which is responsible for site-specific 
integration into chromosomal DNA, it remains episomal and becomes a safe 








produced based on differences in capsid types, which also affect the 
expression (Blits et al., 2010; Ruitenberg et al., 2002). The AAV vector 
system is widely used in CNS research because of its efficient transduction 
with minimal toxicity and immune response (Blits et al., 2003, 2003; Kaplitt et 
al., 1994; McCown, 2005, 2005; McCown et al., 1996; Peel and Klein, 2000; 
Ruitenberg et al., 2004; Taymans et al., 2007; Wu et al., 2006; Zolotukhin et 
al., 2013). To date AAV gene therapy has been successfully used in animal 
models of several CNS disorders including spinal cord injury. For example, 
improved cell survival was observed with AAV vector-mediated expression of 
the glial cell line-derived neurotrophic factor (GDNF) and Bcl-2 expression in 
ALS mice (Azzouz et al., 2000; Mandel et al., 1997). Improved neuronal 
survival and axonal regeneration was also observed in an optic nerve crush 
model through AAV-mediated over expression of BAG1 or reggie1 (Koch et 
al., 2013; Planchamp et al., 2008). AAV-mediated BDNF gene therapy 
ameliorated injured neuronal survival, increased regeneration associated 
genes such as GAP-43 and ßIII-tubulin, and thereby increased axonal 
sprouting in CST and RST lesion models (Blits et al., 2004; Kobayashi et al., 
1997; Kwon et al., 2002a, 2007; Ruitenberg et al., 2004; Vavrek et al., 2006).  
 
Thus, AAV-based gene therapy seems to be a promising strategy for 
targeted therapies to the red nucleus (RN) in rat models of spinal cord lesion. 
In this study, the AAV1/2 hybrid serotype that has AAV2 inverted terminal 
repeats (ITRs) and AAV1 Rep and Cap genes (AAV1/2) was used to induce 
efficient neuronal expression of the target genes in the CNS (Kiyota et al., 
2009; Koch et al., 2013).  
 
1.6.1 Rho and Rho kinase (ROCK) 
Axon growth and regeneration are regulated by actin cytoskeleton dynamics 
of the neuronal growth cone and Rho family members are important 
regulators of actin cytoskeletal dynamics. Rho signal transduction depends 
on the activation of downstream effector kinases such as ROCK. Thus Rho 








regeneration and sprouting (Forgione and Fehlings, 2013; Samuel and 
Hynds, 2010).  
ROCK is a serine/threonine protein kinase with a molecular mass of 
~160kDa. ROCK has two isoforms, namely ROCK1 and ROCK2, which are 
encoded by two different genes. Despite similarities in protein sequence, the 
tissue distribution of ROCK1 and ROCK2 is quite different, representing the 
functional differences of these isoforms in vivo. ROCK1 is predominantly 
expressed in non-neuronal tissues such as heart, lung and skeletal muscle. 
ROCK2 is mainly expressed in the brain tissue and high levels of ROCK2 
expression were reported during postnatal development of the mouse brain, 
especially in the Purkinje cells of the cerebellum, the cerebral cortex and 
hippocampal neurons (Hashimoto et al., 1999; Komagome et al., 2000; 
Matsui et al., 1996; Nakagawa et al., 1996).  
 
One of the reported mechanisms of action of ROCK on spine stability and 
growth cone rearrangement is via phosphorylation of LIM-kinase 1 (LIMK1), 
which in turn inactivates cofilin, an actin depolymerizing factor (Arber et al., 
1998; Ohashi et al., 2000).  Recently, upregulation of ROCK2 was reported 
after spinal cord injury in vivo (Wu et al., 2013). It has been shown previously 
that inhibition of Ras homolog gene family member A (RhoA) or ROCK can 
improve axonal outgrowth in vitro and axonal regeneration after CST lesion 
and optic nerve crush injury in vivo (Dergham et al., 2002; Lehmann et al., 
1999; Lingor et al., 2007). Lentiviral-mediated expression of dominant-
negative ROCK demonstrated increased axonal sprouting and partial motor 
recovery in an RST lesion model in vivo (Wu et al., 2009). Most importantly, 
inhibition of ROCK has also been demonstrated to improve neuronal survival 
in animal models of Parkinson’s disease and amyotrophic lateral sclerosis 
(Tönges et al., 2012, 2014). Thus modulation of ROCK represents a 
promising therapeutic target in SCI research (Tönges et al., 2011; 
Watzlawick et al., 2013). Figure 5 depicts the scar tissue and mechanism of 
Rho-ROCK signaling and myelin inhibitory pathways on growth cone arrest 











Figure 5. Inhibitory pathways for axonal regeneration following SCI. (a) 
Schematic view of the SCI displaying scar tissue formation by the activated 
astrocytes and meningeal cells, which form a growth impermeable 
environment for axons. (b) Activation of myelin inhibitors OMgp, Nogo, MAG, 
CSPGs and inhibitory guidance cues, e.g. ephrins and semaphorins, results 
in subsequent activation of the Rho-ROCK pathway finally leading to the 










Bcl-2-associated athanogene-1 (BAG1) is a multifunctional protein binding to 
Hsp70/Hsc70, which was previously shown to be neuroprotective, anti-
apoptotic and to promote neuronal differentiation (Götz et al., 2005; 
Takayama et al., 1995). Overexpression of BAG1 had neuroprotective effects 
in rodent stroke models via its anti-apoptotic activity and ameliorated 
huntingtin toxicity and aggregation in Huntington’s disease models in vitro 
and in vivo (Jana and Nukina, 2005; Sroka et al., 2009). In addition to its 
neuroprotective effects, BAG1 also induced increased neurite lengths in vitro 
(Kermer et al., 2002). BAG1 mediates its effects on cell growth and 
differentiation via activating the rapidly accelerated fibrosarcoma-1 (Raf-1) 
kinase and its downstream extracellular signal regulated kinase (ERK) (Song 
et al., 2001). Studies in an optic nerve crush model demonstrated that BAG1 
overexpression in retinal ganglion cells resulted in improved cell survival and 
axonal regeneration via activation of Raf-1 signalling and reduction of ROCK 













Figure 6. Schematic model of BAG1-mediated neuroprotection and 
axonal regeneration. BAG1 mediates the activation of the ERK pathway 
and inhibition of the ROCK activity via Raf-1 activation. Activation of ERK 
may enhance the intrinsic capability of neuronal outgrowth, while decrease in 
ROCK activity may regulate actin cytoskeleton rearrangement in the growth 
cones. BAG1 activates Bcl-2 and Hsp-70 by its Hsp70-binding domain thus 
enhancing neuronal survival. Full lines: Direct interaction; Dashed lines: 
Indirect interaction. Pointed end: stimulation, bar end: inhibition. Image was 
adapted from Planchamp et al., 2008.  
 
1.6.3 microRNA-134 
Micro-RNAs (miRNAs) are a family of small non-coding RNAs (~21-25 
nucleotides) that regulate mRNA translation by imperfect base pairing 
interaction with protein-coding mRNAs. Depending on the degree of 
sequence complementarity at the 3′-untranslated region of the mature 
mRNAs they can lead to either a cleavage or a reduction in its translational 
efficiency of the target mRNA (Zhang et al., 2012). miRNA-134 is a brain-
specific miRNA, which is expressed in the rat dendrite spine compartments of 
hippocampal pyramidal neurons. It was reported to regulate cell proliferation 
and apoptosis in the lung septa development (Zhang et al., 2012). miRNA-
134 was also reported to regulate dendrite spine development via BDNF and 








Schratt et al., 2006). LIMK1 is a kinase, which is known to regulate the actin 
cytoskeleton and could thus be responsible for miRNA-134 effects on axonal 
regeneration (Numakawa et al., 2011; Schratt et al., 2006). Since LIMK1 is a 
well-known target of ROCK, miRNA-134 indirectly can regulate the same 
pathways, which are regulating axonal outgrowth following injury (Ohashi et 
al., 2000). This renders miRNA-134 an especially interesting target for 
studying axonal regeneration in the CNS. 
  
1.6.4 Reggie1 
Reggie proteins (reggie1 and reggie2) are two cell surface proteins, which 
were first discovered in retinal ganglion cells (RGC) of the goldfish during 
axonal regeneration (Schulte et al., 1997). In an independent study, they 
were also identified as insoluble floating lipid raft fraction the membranes, 
hence called flotillins (Bickel et al., 1997) and are (reggie1/flotillin2 and 
reggie2/flotillin1) used as lipid raft markers. Both proteins are evolutionary 
conserved, ubiquitously expressed in various cell types and are well-known 
for selected cargo transport to specific target cells areas such as cell-cell 
contacts, T-cell caps, and growth cones (Stuermer, 2010). Recent studies 
had given some insight on the possible molecular mechanism of reggie in 
axonal regeneration in mammals. Down-regulation of reggie leads to 
abnormally bulged, malformed growth cones, reduced axonal regeneration, 
growth cone elongation in zebra fish and reduced cell differentiation of 
hippocampal neurons (Munderloh et al., 2009). Further, down-regulation of 
reggie has also led to an imbalance in activation of Rho GTPases, Rac, Rho, 
and cdc42, which in turn activated downstream effectors such as Ras, cofilin 
and focal adhesion kinase (FAK) (Langhorst et al., 2008; Munderloh et al., 
2009; Schrock et al., 2009). In support of this data, reggie was also reported 
to recruit cellular prion protein (PrPc)-mediated N-cadherin at cell-cell 
contacts, which further strengthens its role in controlling actin cytoskeleton 
turnover through Rho-GTPases (Ren et al., 2013; Solis et al., 2012; 
Stuermer, 2010). Recently, expression of reggie1/flotillin2 was reported to be 
down-regulated following acute SCI, but upregulated in later phases and 








recovery in a rat model (Santiago et al., 2013). In contrast, our laboratory has 
shown that AAV-mediated over-expression of reggie1/flotillin2 improved 
axonal regeneration in an optic nerve crush model of rat (Koch et al., 2013).  
 
1.7 Aims of the thesis 
The current study was designed to evaluate the potential of AAV-based gene 
therapy by overexpression of BAG1, reggie1, miRNA-134, or shRNA-
mediated downregulation of ROCK2 alone and in combination with an anti-
scarring treatment (AST) in an established CNS lesion model, the dorsal 
spinal cord hemisection. The target molecules were chosen to combine both 
neuroprotective and pro-regenerative properties and the AST with the iron-
chelating agent BPY-DCA was chosen to ameliorate the scar formation 
further improving axonal regeneration. To this point, several substudies were 
designed: 
 
1. A pilot study aimed at investigating the effects of a combination 
treatment with AAV-based over-expression of BAG1 and local 
application of BDY-DCA on axonal sprouting and motor recovery at 16 
weeks after dorsal spinal cord hemisection in rats.  
 
2. A further study aimed to evaluate the method of anterograde tract 
tracing of the RST with biotinylated dextran amine (BDA) and AAV-
mediated expression of the fluorophores DsRed (AAV.DsRed) and 
EGFP (AAV.EGFP) after the dorsal spinal cord hemisection in the rat.  
 
3. Finally the effect of different target gene therapies by AAV-based over-
expression of BAG1, reggie1, miRNA-134 and ROCK2-shRNA was 
investigated. Here, the effect of AAV-mediated gene therapy on RN 
neuronal survival, axonal sprouting of RST and motor recovery at 12 
weeks after unilateral dorsal spinal cord hemisection was studied. In 
addition to the evaluation of the target gene therapies, we aimed to 
demonstrate feasibility and limitations of AAV-mediated protein 
overexpression vs. shRNA- or miRNA-mediated downregulation in this 












Table 1. List of the instruments used in this study. 
Instrument             Company 
ApotomeTM Zeiss, Göttingen, Germany  
Autoclave Systec, Greiz, Germany  
Dental drill P10 burr, Meisingen, Germany 
CCD camera AxioCam Zeiss, Göttingen, Germany  
Cryostat Leica, Nussloch, Germany  
Freezers (-80° C) Heraeus, Hanau, Germany  
Ice machine Scotman® Frimont, Milan, Italy  
Micro4 smart controller World Precision Instruments, Florida, USA  
Microwave oven Bosch, Stuttgart, Germany  
Nanoliter2000 injector World Precision Instruments, Florida, USA  
Peristaltic pump, IP4 Ismatec, Glattbrugg,Switzerland  
pH-meter Sartorius, Göttingen, Germany  
Pipettes Gilson, Villiers le Bel, France  
Refrigerators (4° C and -20° 
C) 
Liebherr, Biberach, Germany  
Scales Sartorius, Göttingen, Germany  
Stereotactic frame David Kopf Instruments, California, USA 
Surgery microscope Zeiss, Göttingen, Germany  
Surgical and dissection tools Fine Sceince Tools, Heidelberg, Germany 
Surgical suture  Ethicon, Johnson-Johnson, Livingston, U.K 
Osmotic mini-pumps  Model-2004, ALZET®, Cupertino, CA 
Table centrifuges Eppendorf, Hamburg, Germany  
Ultracentrifuge Sorvall DuPont Instruments, Bag Homburg, Germany  
Video camcorder  Canon LEGRIA-HF M36, Miami, USA 
Vortex mixer NeoLab, Heidelberg, Germany  
Water bath GFL, Burgwedel, Germany  










2.2 Chemicals and Consumables 
Table 2. List of chemicals and consumables used in this study. 
 
 
Product Reference  
  
Bovine serum albumine 
(BSA)  
Sigma, Taufkirchen, Germany  
 
Braunol®  (B.Braun Melsungen AG, Berlin, 
Germany) 
2,2’-bipyridine-5, 5’-
dicarboxylic acid (BPY-DCA) 
Sigma, Taufkirchen, Germany  
 
Cryomatrix  Cryomatrix (ThermoScientific, 
Schwerte, Germany), 
D (+)-glucose  Sigma, Taufkirchen, Germany  
D (+)-sucrose  AppliChem, Darmstadt, Germany  
Ethanol absolute  AppliChem, Darmstadt, Germany  
Formaldehyde  Merck, Darmstadt, Germany  
Glycerine  Sigma, Taufkirchen, Germany  
Glycerol  Roth, Karlsruhe, Germany  
Glycine  AppliChem, Darmstadt, Germany  
Hydrogen peroxide (H2O2)  Merck, Darmstadt, Germany  
Magnesium chloride (MgCl2)  AppliChem, Darmstadt, Germany  
Mowiol  CalbioChem, La Jolla, CA, USA  
Normal goat serum 
N-propyl-gallate (NGS)  
PAA, Coelbe, Germany  
Sigma, Taufkirchen, Germany 
Paraformaldehyde (PFA)  AppliChem, Darmstadt, Germany  
PBS (1x Dulbecco’s, powder)  AppliChem, Darmstadt, Germany  
Sodium acetate 
Sodium azide (NaN3)  
Fluka, Taufkirchen, Germany  
Sigma, Taufkirchen, Germany 
Sodium bicarbonate (Na2CO3)  Sigma, Taufkirchen, Germany  
Sodium chloride (NaCl)  AppliChem, Darmstadt, Germany  
Sodium hydroxide (NaOH) AppliChem, Darmstadt, Germany 
TRIS-base  AppliChem, Darmstadt, Germany  
Triton X-100  Sigma, Taufkirchen, Germany  









All general  laboratory chemicals and consumables were purchased from 
AppliChem, (Darmstadt, Germany) and Sarstedt (Nümbrecht, Germany)  
unless otherwise specified. 
 
2.3 Solutions and Buffers 
 
2.3.1 Mowiol 
5 g of mowiol were dissolved in 20 ml sterile PBS under constant stirring for 4 
h at 4°C, to which 10 ml of glycerine were added and dissolved on a shaker 
for 16 h at 4°C. The mixture was then centrifuged for 15 min at 4000 rpm 
(1699 g) and the supernatant was removed carefully. The pH was adjusted to 
8.0 and finally 0.3 ml of sodium azide (2% w/v) and a tip of N-propyl-gallate 
were added to 10 ml of the solution, which was centrifuged for 20 min at 
4000 rpm (1699 g). 
 
2.3.2 Paraformaldehyde (PFA) 4% 
40 g of PFA were dissolved in 700 ml of filtered PBS under constant heating 
(55°C). A small pellet of NaOH was added to the PBS to enhance the 
dissolution of PFA. pH was carefully adjusted to 7.4 and the solution was 
made up to 1000 ml with PBS was stored at 4°C. 
 
2.3.3 1x PBS 
9.55 g of PBS powder were dissolved in 1000 ml of distilled H2O, sterilized 
and filtered. 
2.3.4 10 %, 20 %, 30 % of sucrose (sucrose for cryoprotection) 
10 g, 20 g or 30 g of sucrose were dissolved in 100 ml of PBS to prepare 10 








2.3.5 10% Normal Goat Serum (NGS)  
1000 µl of NGS were dissolved in 10 ml 1x PBS. 
 
2.3.6 Citrate buffer (antigen retrieval solution) 
0.21 g of citric acid monohydrate (0.1 M) were dissolved in 100 ml of distilled 
H2O. The pH was adjusted to 6 with 1 M NaOH. 
 
2.3.7 Blocking solution for immunohistochemistry 
100 µl of 10 % (w/v) normal goat serum, 0.01 g of bovine album serum, 0.3 % 
(w/v) Triton X-100 were added to 1 ml of 1 x PBS. 
 
2.3.8 TRIS buffer, 20 mM, pH 8.1 
2.1 g of TRIS base (C4H11NO3) was dissolved in 1000 ml of distilled H2O. 
The pH was adjusted to 7.9 with HCl. 
 
2.3.9 BPY-DCA (2,2’-bipyridine-5, 5’-dicarboxylic acid), 40 mM, pH 7.4 
Solution 1: 20.1 mg of BPY-DCA powder were dissolved in 2.06 ml  
TRIS buffer (pH 5.5).  
Solution 2: 20 µl 5 M NaOH (pH 6.1) were added to 1.9 ml of solution 1.  
Solution 3: 5 µl 5 M NaOH (pH 8.4) were added to 1.7 ml of solution 2 and 









2.4 Primary Antibodies 
 
Table 3. List of primary antibodies used in this study 
Antibody  Company  
Mouse anti-NeuN (1:200)  Millipore (Billerica, USA) 
Goat anti-ROCK2 (1:50)  Santa Cruz Biotechnology (Texas, USA)                                                                            
Rabbit anti-BAG1 (1:250)  Santa Cruz Biotechnology (Texas, USA) 
Rabbit anti-GAP43 (1:500)  Abcam (Cambridge, UK) 
Rabbit anti-synaptophysin (1:1000)  Sigma Aldrich (St. Louis, USA) 
Rabbit anti-GFAP (1:200)  Dako (Hamburg, Germany) 
Chicken anti-GFP (1:250)   Abcam (Cambridge, UK) 
 
2.5 Secondary Antibodies 
 
Table 4. List of secondary antibodies used in this study.  
Antibody  Company 
Alexa Fluor® 488 conjugated goat                   Invitrogen-Molecular Probes 
   anti-chicken antibody  (Carlsbad, USA) 
Alexa Fluor® 647 conjugated donkey  Invitrogen-Molecular Probes 
   anti-goat antibody  (Carlsbad, USA) 
Cy5 conjugated goat anti-mouse antibody      Dianova (Hamburg, Germany) 
Cy3 conjugated goat anti-mouse antibody      Dianova (Hamburg, Germany) 
Cy3 conjugated goat anti-rabbit antibody        Dianova (Hamburg, Germany) 
Cy2 conjugated goat anti-rabbit antibody        Dianova (Hamburg, Germany) 










2.6 Anterograde tracing dyes 
 
Table 5. List of anterograde tracers used in this study. 
Tracer Dye                     Company 
Biotinylated dextran amine (BDA)                Invitrogen-Molecular Probes 
MW 10, 1000  (Carlsbad, USA) 
Alexa Fluor® 647 conjugated cholera            Invitrogen-Molecular Probes 









Adult female Wistar rats weighing 230-250g were used for all experiments 
(Charles River, Germany). Animals were maintained at 12/12 h light and dark 
cycle with ad libitum food and water. All animals were sacrificed by CO2 
insufflations followed by transcardial perfusions. All animal experiments were 
performed following the regulations and legislation of the local animal 
research council of the Lower Saxony State (Braunschweig), Germany.  
 
3.2 Cloning of viral vectors 
The AAV1/2 vector expressing BAG1 and the fluorophore EGFP under 
control of a human synapsin promoter (AAV.BAG1) was kindly provided by 
Sebastian Kügler (Kügler et al., 2001; Planchamp et al., 2008). All other AAV 
were kindly provided by Uwe Michel and Jan Koch. Viral vector maps are 
shown in Annexes, supplementary images. 
 
The control vectors AAV1/2-EGFP (AAV.EGFP) (Gen-Bank ID: HQ416702) 
and AAV1/2-DsRed (AAV.DsRed) (Gen-Bank ID: AY640633) expressing 
EGFP or DsRed driven by a human synapsin promoter and the nonsense 
protein CytBAS under control of a H1 promoter were used. The cloning of 
these vectors has been described earlier by Koch et al., 2011. 
 
The AAV1/2-reggie1 (AAV.reggie1) expressing a fusion-protein of reggie-1 
and EGFP under control of a human synapsin promoter was used and been 
described earlier by Koch et al., 2011.  
 
The AAV1/2-shRNA-ROCK2 (AAV.sh.ROCK2), AAV1/2-shRNA-firefly 
(AAV.sh.firefly) and AAV1/2-miRNA-134 (AAV.miRNA-134)) were expressing 
the respective shRNA or miRNA-134 under control of a H1-promoter and the 
fluorophore EGFP driven by a human synapsin promoter were used.  They 
were cloned according to a protocol published elsewhere (Michel et al., 
2005). In brief, 200 pmol of the forward and reverse primers containing the 







water and 25µl of 2x annealing buffer (20 mM TRIS, pH 7.8, 100 mM NaCl, 
and 0.2 mM EDTA). The solution was boiled for 5 min and then cooled to 
room temperature. Annealed oligos (200 fmol) were ligated to 22.5 fmol of 
the Bgl2/Hind3-cut backbone fragment of pSUPER-hSyn-EGFP-CytB-AS 
(GenBank ID: AY640629; Michel et al., 2005).  
 
The sequences of the shRNA primers were as follows (in bold: sequence of 
the respective siRNA-sense and -antisense strand, in italics: sequence of the 
hairpin turn):  
 
For AAV.sh.ROCK2:  
   ROCK2-shRNA forward primer:  
GATCCCC-TGCAAAGTTTATTATGATATA-CTTCCTGTCA-
TATATCATAATAAACTTTGCA-TTTTTGGAAA;  
   ROCK2-shRNA reverse primer:  
AGCTTTTCCAAAAA-TGCAAAGTTTATTATGATATA-
TGACAGGAAG- TATATCATAATAAACTTTGCA-GGG.  
 
For AAV.sh.firefly (see Malik et al., 2006): 
   Luciferase-2 forward primer:  
GATCCCCGTGCGCTGCTGGTGCCAACCCCTTCCTGTCAGGGTTG
GCACCAGCAGCGCACTTTTTGGAAA. 
   Luciferase-2 reverse primer 
AGCTTTTCCAAAAAGTGCGCTGCTGGTGCCAACCCTGACAGGA
AGGGGTTGGCACCAGCAGCGCACGGG; 
    
For AAV.miRNA-134: 
   miRNA-134 forward primer 
CAGGGTGTGTGACTGGTTGACCAGAGGGGCGTGCACTTTGTTC
ACCCTGTGGGCCACCTAGTCACCAACCCTC; 









This step resulted in the vectors pSUPER-hSyn-EGFP-H1-ROCK2-shRNA 
and pSUPER-hSyn-EGFP-H1-luc2 that were then digested with BstB1/Hind3. 
The resulting inserts containing the H1-promoter and the ROCK2- or firefly-
shRNA were cloned into a BstB1/Hind3-cut pAAV-9(5)hSyn-EGFP-CytbAS-
ohneNot (Gen- Bank ID: HQ416702) resulting in the vector pAAV-9(5)hSyn-
EGFP-H1-ROCK2-shRNA or pAAV-9(5)hSyn-EGFP-H1-firefly-shRNA or 
pAAV-9(5)hSyn-EGFP–miRNA-134 which was then used for AAV production.  
 
Production of AAV (serotype 1/2) was performed as reported before 
(Zolotukhin S et al., 1999). Briefly, 293-HEK cells were transfected with 
calcium phosphate, HEPES buffered saline and a plasmid mix of pAAV-RC, 
pH21, pHELPER and the respective pAAV expression vector in a 0.5:0.5:1:1 
molar ratio. The pH21 vector, expressing AAV serotype 1 capsids, was a gift 
from Helen Fitzsimons (Neurologix, Inc. OSU Comprehensive Cancer 
Center, Columbus, OH) and Matthew During (Molecular Virology, 
Immunology, and Medical Genetics, Columbus, OH). 48 h after transfection, 
cells were harvested and AAV were purified by dialysis and virus gradient 
centrifugation in iodixanol. Fast protein liquid chromatography (FPLC) was 
performed to obtain high titer viral stocks. The virus stocks were then tested 
on primary cortical neurons for transduction efficacy and toxicity and viral 
titers were determined using qPCR. 
 
3.3 Experimental set-up and animal groups  
3.3.1 Pilot project: Effects of the combination of BAG1 overexpression 
and anti-scarring treatment with BPY-DCA in a rat model of dorsal 
spinal cord hemisection. 
 
A list of treatment groups is given in Table 6 and the sketch of the 












Table 6. List of treatment groups for combination of BAG1 with anti-
scarring treatment  
 
Group AAV injections in the 
RN 
Short name 
used in this 
thesis 







A AAV1/2-BAG1-EGFP AAV.BAG1 1x 108 6 
B AAV1/2-BAG1-EGFP 
+ BPY-DCA  
AAV.BAG1 + 
AST * 









 + 20mM (pH 
8.1) 
6 
D AAV1/2-EGFP (as a 
control of A) 
AAV.EGFP  3.4 x 107 6 
E AAV1/2-EGFP + 
BPY-DCA (as a 
control of B) 
AAV.EGFP + 
AST* 
3.4 x 107 + 40mM (pH 
7.4) 
6 
F AAV1/2-EGFP + 
TRIS buffer (as a 
control of C) 
AAV.EGFP + 
ASB* 




*AST=anti-scarring treatment (BPY-DCA) 
*ASB=anti-scarring buffer (TRIS buffer) 
 
 
All animals were also injected in the cortex with AAV1/2.DsRed (1.4 x 108 
TU) in addition to the AAV.BAG1 or AAV.EGFP injections into the RN. The 
number of animals that were used for data evaluation in each group (after 
elimination because of foot lesion and insufficient viral transduction at RN) 
were AAV.BAG1=3; AAV.EGFP=2; AAV.BAG1 + AST=2; AAV.EGFP + AST 
=1; AAV.BAG1 + ASB=2; AAV.EGFP + ASB=1. (AST=anti-scarring treatment 
(BPY-DCA); ASB=anti-scarring buffer (TRIS buffer)). 











Figure 7. Experimental set-up for the combination treatment with 
AAV.BAG1 and AST in a rat model of spinal cord dorsal hemisection. 
(a) Scheme of the experimental set-up showing stereotactic AAV injections in 
the RN and cortex (CX), dorsal hemisection and osmotic mini-pump 
implantation (for AST) at thoracic level 8 (Th8). b) Time course of the 
experiments. RN=red nucleus; CX=cortex; AAV=adeno associated virus; 
SCI=spinal cord injury, AST=anti-scarring treatment; CTB=cholera toxin B. 
 
3.3.2 Anterograde tracing of RST before and after dorsal spinal cord 
hemisection 
List of treatment groups is given in Table 7 & 8. The model sketch of the 















Table 7. List of treatment groups for tracing of RST before and after 
dorsal spinal cord hemisection. 
 
 
1st RN injection 2nd RN injection Number of 
animals 
AAV1/2-EGFP (3.4 x 107  
TU/μl) 
BDA  3 
AAV1/2-EGFP (3.4 x 107  
TU/μl) 





Figure 8. Experimental set-up of anterograde tracing of RST before and 
after dorsal spinal cord hemisection. (a) Scheme of the experimental 
approach showing stereotactic AAV injections in the RN and dorsal 
hemisection at thoracic level 8 (Th8). (b) Time course of the experiments. 
RN=red nucleus; AAV=adeno associated virus; SCI=spinal cord injury; 












Figure 9. Experimental set-up of anterograde tracing of RST 
immediately after dorsal spinal cord hemisection. (a) Scheme of the 
experimental approach showing stereotactic AAV injections in the RN and 
dorsal hemisection at thoracic level 8 (Th8) (b) Time course of the 







Table 8. List of treatment groups for tracing of the RST immediately 
after dorsal spinal cord hemisection 
 
Anterograde tracing with RN injection immediately after dorsal 
spinal cord hemisection 
Number of 
animals 
AAV1/2-EGFP (3.4 x 107  TU/μl) 3 
 
3.3.3 Effects of AAV.BAG1, AAV.reggie1, AAV.miRNA-134 and 
AAV.sh.ROCK2 on RST in a rat model of dorsal spinal cord hemisection 
List of treatment groups were listed in Table 9. The model sketch of the 
experiment and the time plan of the experiment are shown in Figure 10. 
 
 
Table.9 List of treatment groups for gene therapy with AAV.BAG1, 
AAV.reggie1, AAV.miRNA-134 and AAV.sh.ROCK2 experiment. 
 









AAV.miRNA-134 7.2 x 108  10 
B AAV1/2-EGFP-
BAG1 




AAV.sh.ROCK2 3.5 x 108 15 
D AAV1/2-EGFP- 
reggie1 





(as a control of 
A&C) 
AAV.sh.firefly 9.4 x 108 11 
F AAV1/2-EGFP 
(as a control of 
B & D) 












Figure 10. Experimental set-up for anterograde tracing of RST 
immediately after dorsal spinal cord transection. (a) Scheme of the 
experimental approach showing stereotactic AAV injections in the RN and 
dorsal hemisection at thoracic level 8 (Th8). (b) Time course of the 
experiments. RN=red nucleus; AAV=adeno associated virus; SCI=spinal cord 
injury. 
 
The number of rats that were used for quantification of the data in this 
experiment (after elimination of rats due to foot lesion and partial lesion) were 
AAV.EGFP, n=4; AAV.BAG1, n=8, AAV.sh.firefly, n=7, AAV.sh.ROCK2, n=8, 
AAV.reggei1, n=7, AAV.miRNA-134, n=5. 
 
3.4 Animal surgeries 
3.4.1 Stereotactic injection of AAV into the brain 
Successful gene therapy studies rely on the efficient transduction of the 
target tissue. The viral injections for the RN and CX projections were done 







Wiessner et al., 2003). Rats were deeply anesthetized using 2–3 % 
Isoflurane anaesthesia in O2 and NO2 (1: 2) and were placed in a stereotaxic 
frame with horizontal skull position fixed by ear and tooth bars. To expose the 
skull, an incision in the rostro-caudal direction through the skin was made. 
The defined stereotactic coordinates for injections were measured with the 
intersection points of lambdoid and sagittal suture lines (Figure 11), 
according to the rat brain atlas (Paxinos and Watson, 1998). The heights of 
lambda and bregma were adjusted to obtain a horizontal skull position. The 
bregma coordinates for the RN injections were antereoposterior (AP): -6.0 
mm; mediolateral (ML): +0.7 mm; and dorsoventral (DV): -6.8 mm from the 
dura mater. The bregma coordinates for the cortex injections were: AP: -2.0 
mm; ML: +2.4 mm; and DV: -1.2 mm from the dura mater. The distance 
between the bregma and lambda was measured for all the animals before 
measuring the coordinates for the injections. The general bregma and 
lambda distance for the adult Wistar rats was 9 mm (Paxinos et al., 1985). 
Based on this distance the coordinates for the RN injections were; (AP): -6.0 
mm; mediolateral (ML): +0.7 mm; and dorsoventral (DV): -6.8 mm. The 
bregma coordinates for the cortex injections were: AP: -2.0 mm; ML: +2.4 
mm; and DV: -1.2 mm. For any variations in the bregma and lambda distance 
(generally less than 9 mm in our case), the coordinates for the RN and CX 
injections were adjusted in correlation to the bregma and lambda length to 
avoid possible anatomical variations among animals (Paxinos et al., 1985). 
For e.g., if the bregma and lambda distance was measured as 8.5 mm, the 
coordinates for the RN injections would be AP: -5.66 mm, ML: +0.66 mm and 
DV: -6.42 mm. After measuring the coordinates, the target location was 
marked and a hole was made using a dental drill at the marked reference 
points. The virus was injected using a heat pulled glass capillary attached to 
nanolitre2000. The controlled and gradual infusion of AAV into the brain was 
performed using a micro injector pump system at a speed of 0.3 μl/min. The 
applied volume of virus (Table 6, 7, 8 and 9) or anterograde tracing dye BDA 
or CTB was 2μl. Finally, the skull was closed by suturing the skin using a 3/0 
non-absorbable surgical suture. After the experiment, the animals were kept 
on a warming pad until awake and were then brought back to the home cage. 











Figure 11. Rat skull suture lines locating the bregma and lambda intersect 
points for calculating coordinates for stereotactic brain injections. Figure from 
Paxinos and Watson, 1998. 
 
3.4.2 Right dorsal hemisection of the spinal cord 
The spinal cord lesion was performed as reported by (Ruitenberg et al., 
2004). In brief, under 2–3 % Isoflurane anaesthesia in O2 and NO2 (1: 2), the 
back of the animal was shaved and disinfected and a longitudinal injection 
was made using a scalpel. The fat layer on the back muscles was gently 
separated from the muscles and fixed aside with the help of a hook. The 
back muscles were then split and gently pulled aside to expose the target 
vertebra. Counting back the spines from the large vertebra Th2 until Th8 
identified the target spines for the laminectomy. A big blood vein running 
between Th4 and Th5 (in ~80% of the rats) could also be used to locate Th5 
(Figure 12). This has been used as further confirmation for counting target 
vertebra (de Medinaceli, 1986). After identifying the target vertebrae, 
laminectomy was performed at thoracic level 8 (Th8) using a bone cutter to 
expose the spinal cord. Care was taken not to damage the spinal cord with 
the rough edges of the bone after laminectomy by trimming off the rough 
edges. The dorsal right half of the spinal cord was transected at Th8 using a 
pair of micro-scissors marked at a depth of 1.25 mm. Finally the back 







operation site was disinfected with Braunol®. During the whole operation, the 
body temperature of the animal was maintained at 37°C using a heating pad. 
After the operation, animals were given 5 ml of Ringer solution 
subcutaneously to substitute for loss of fluids during the operation. 
Postoperatively, an antibiotic (Cotrimoxazol; 15 mg/kg body weight) and an 
analgesic agent (Buprenorphine; 0,05 mg/kg body weight) were applied for 3 
days once daily. The bladder was emptied manually if necessary. Animals 
were taken care post-operatively as described in section 3.4.4.  
 
 
Figure 12. Rat spinal landmarks for counting the spines at thoracic level. 
Blue arrow located the Th2 and big blood vein running between Th4 and Th5. 
Figure modified from de Medinaceli, 1986. 
 
3.4.3 Osmotic mini-pump implantation for the anti-scarring treatment 
delivery to the spinal cord after dorsal hemisection 
Osmotic mini-pumps were used to continuously deliver pharmacological 
treatments (anti-scarring treatment) to the spinal cord lesion site. The 
osmotic mini-pump implantations were done in collaboration with the lab of 
Prof. Dr. Hans Werner Müller, Düsseldorf according to (Klapka et al., 2005). 
A schematic illustration of the osmotic pump implantation is given in Figure 
13. In brief, osmotic mini-pumps were filled with either BPY-DCA or TRIS 
buffer according to manufacturer’s instructions (ALZET®, Cupertino, CA) 











of 1: 2) spinal cord injury was performed as described in section 3.4.2 with 
minor alterations. In brief, laminectomy of vertebrae at thoracic levels 8, 9 at 
Th11 were performed. After right dorsal hemisection at thoracic level 8 (Th8), 
the dura mater was stitched with a 10/0 surgical suture to prevent leakage of 
CSF and the pharmacological fluid applied. One end of the catheter was 
inserted at Th11 and pulled to the direction of lesion via Th10 and a small 
piercing was made through the dura mater rostral to the lesion to insert the 
catheter. The catheter was placed onto the lesion through the piercing and 
was stabilized by stitching it to the dura mater. The other end of the catheter 
was connected to the osmotic mini-pump filled with the respective 
pharmacological treatments (anti-scarring treatment (AST) with BPY-DCA or 
anti-scarring buffer treatment (ASB)). Muscles and the skin were sutured on 
the lesion side by placing the pump on the back of the animal. 5 ml of Ringer 
solution were injected subcutaneously immediately after the operation to 
substitute lost fluids during operation and rats were kept warm under a 










Figure 13. Schematic representations of the osmotic mini-pump 
implantation in the spinal cord of rats.  (a) Laminectomy at thoracic 
vertebrae 8 and 9, and another laminectomy between vertebrae 10 and 11 
(arrow), lateral view. (b) Laminectomy of the vertebrae 8, 9 and part of the 
vertebrae 11, top view. (c) Spinal cord lesion at Th8. (d) Insertion of the 
catheter between the vertebrae 10 and 11. (e) A hole was made  
approximately 5 mm away from the lesion in the outer meninges (dura mater) 
from where the catheter intrathecally runs to the lesion site beneath the dura 
mater. (f) Lateral view of the catheter above and below the dura mater. (g) 
After inserting the catheter, the osmotic minipump was connected to the 









3.4.4  Pre- and post-operative care of the animals 
All animals were given Metamizole (Metapyrin® 1.33 mg/ml) in drinking water 
2 days pre-operation to let the animals get used to the taste of the drug. This 
treatment was continued for 5 days after spinal cord lesion and osmotic 
pump implantation in addition to the injectable analgesic. 30 minutes prior to 
the surgery, using Isoflurane anaesthesia, an analgesic (Buprenorphine; 0.05 
mg/kg body weight) was given subcutaneously. Immediately after the 
operation, 5 ml of sterile saline water (Ringer solution) were given 
subcutaneously to substitute lost fluids during the operation. The animal was 
kept warm under a warming lamp until awake and was then returned to the 
home cage provided with moist food in a petridish for 3 days. Post-operation, 
an antibiotic (Cotrimoxazol; 15 mg/kg body weight, once a day) and an 
analgesic agent (Buprenorphine; 0.05 mg/kg body weight, twice a day) were 
applied for 3 days. The bladder was emptied manually if necessary and the 
animals were checked regularly for general health conditions and autophagy 
of the toes. If animals were found with foot lesion or toes biting, an oral 
treatment was given with Meloxydyl (Metacam®  0.5 mg/kg body weight once 
a day orally) and a topical wound spray applied to the affected limbs up to 5-
7 days. Animals showed no health improvements (with swollen toes and foot) 
were sacrificed and eliminated from the study.  
 
3.4.5 Perfusions and tissue processing 
Transcardial perfusions allows uniform and rapid fixation of the tissue for the 
immunohistochemistry and the animals circulatory system distribute the 
fixative throughout body allowing preservation of tissues ultrastructure and 
stabilizes protein and peptide confirmation (Gage et al., 2012). For the brain 
and spinal cord cryosections, transcardial perfusions were performed in all 
animals. The animal was deeply anaesthetized by insufflation of CO2. 
Immediately after cessation of breathing, the animal was fixed upside down 
on a rack and a ~10 cm long cut along the sternum was made. The 
diaphragm was cut laterally on both the sides towards the head across ribs 
and in parallel to the lungs. A small pair of rat tooth forceps was used to 







scalpel. Then the cannula was inserted in to the slit and directed up through 
the left ventricle into the ascending aorta. Clamping the aorta with mosquito 
hemostat forceps stabilized the cannula. With the aid of a peristaltic pump 
cold PBS (pH 7.4) was injected through the cannula to flush out the 
circulatory blood. Once the blood flow from the nose outlet became clear or 
colorless (after running around 200 ml of PBS), PBS flow was replaced by 
cold 4 % PFA in 1 x PBS (pH 7.4). A successful PFA-perfusion was indicated 
by the stiffness of the tail and neck of the animal. The spinal cord and the 
brain samples were dissected carefully and post-fixed in 4 % PFA overnight. 
The samples were then dehydrated in gradient sucrose solutions of 10 %, 20 
% and 30 % (24 hrs. in each concentration) and finally preserved at -20°C 




Following embedding the brain and the spinal cord sections in the cryomatrix, 
the coronal brain sections at a thickness of 30 µm (Figure 14) were made at 
the level of RN (approximately at bregma 5.6 to 6.4, anatomy guidelines from 
rat brain atlas of Paxinos and Watson, 1998) to check the viral transduction 
at RN and for the quantification of RN neurons. The cryomatrix embedded 
spinal cord tissue was dissected into three blocks, a block of 1 cm diameter 
with the lesion in the center, a 2 cm cervical block (C2-C6) and a 2 cm 
thoracic block (Th1-Th5) proximal to the lesion (Figure 14). The lesion block 
was then cryosectioned horizontally (slice thickness 30 µm) at the level of 
RST. Transverse sections of cervical block (C2-C6) and thoracic block (Th1-
Th5) were made at a thickness of 30 µm and all cryosections were dried at 











Figure 14. Schematic representation of the cryosectioning strategy of 
the brain and spinal cord. Schematic image representing the location of the 
EGFP-labeled RN and RST (green) coronal brain sections were made at the 
RN level (orange lines). The lesion block of the spinal cord (1 cm) was cut 
into horizontal sections and the thoracic spinal cord (Th1-Th5) and cervical 
levels (C1 to C5) were cut into transverse sections. The orange squares 
represent the orientation of the sectioning. 
 
3.5.2 Immunohistochemistry 
Immunohistochemistry is a process of detecting proteins localized within a 
tissue by exploiting the principle of antibodies that bind specifically to the 
protein of interest. A secondary antibody conjugated to a fluorophore that 
binds specifically to the primary antibody thereby allows specific visualization 
of the target protein.   
 
All specimens for immune staining were thawed at 37°C, washed in PBS and 
were outlined on the slides with a Pap Pen to prevent the spilling of liquids. 
All immunohistological stainings were performed using the heat-mediated 
antigen retrieval method with citrate buffer at pH 6 followed by blocking in 
10% NGS, 1% BSA and 0.3% TritonX-100 for 1.5 hr at room temperature 
(RT). Subsequently, the sections were incubated with respective primary 
antibodies over night at 4°C in a moist chamber. The spinal cord horizontal 
sections were incubated with polyclonal rabbit anti-GFAP antibody (1:200), 
polyclonal rabbit anti-GAP43 antibody (1:500).  The spinal cord transverse 
sections were incubated with polyclonal rabbit anti-GFAP antibody (1:200), 
mouse monoclonal anti-NeuN antibody (1:200), rabbit polyclonal anti-
synaptophysin (1:1000) or chicken polyclonal anti-GFP (1:250).  The 
midbrain sections were incubated with rabbit polyclonal anti-BAG1 antibody 







anti-NeuN antibody (1:200). All the sections were then incubated with 
respective secondary antibodies coupled to Cy3 (1:500) or Cy5 (1:250) or 
Alexa Fluor® 488 for 1 hr at RT (please refer to Table 3 & 4 for the list of the 
antibodies used). After further washing thrice with PBS, sections were 
counter stained with DAPI (4‘,6-Diamidino-2-phenylindole) for nuclear 
labeling. All the sections were air-dried, mounted with Mowiol and were 
stored at 4°C for the microscopic imaging.  
 
3.6 Data analysis and quantifications 
3.6.1 NeuN counting for RN cell survival quantification 
 
For the RN neuron number and soma size quantification, midbrain sections 
were immunolabelled with anti-NeuN antibody for consistent labeling of the 
atrophied RN neurons after axotomy, as shown by (Kwon et al., 2002b). The 
RN was identified by the distinct morphology of magnocellular RN neurons 
with the adjacent midbrain structures of the oculomotor nerve fibers and the 
substantia nigra as anatomical references (Carter et al., 2011). Three of the 
brain sections per animal at the level of the RN were used for quantification. 
Images were sampled using a fluorescence microscope (AxioPlan equipped 
with a CCD camera and MosaiX software, Zeiss, Goettingen, Germany) 
using a 10 x optical lens. The number and size of NeuN-positive cells with 
clear DAPI nuclei were quantified at the magnocellular portion of the RN 
using AxioVision LE software. NeuN quantifications were made in the 
injected RN (lesioned RST) and uninjected RN (unlesioned RST), which 
served as internal control in each animal. RN neurons were classified 
according to their size. The comparisons among the groups were always 
made with AAV.BAG1 vs. AAV.EGFP and AAV.sh.ROCK2 vs. AAV.sh.firefly 
as respective control groups.  
 
3.6.2 Quantification of axonal sprouting  
 
Sprouting was defined as projections or branches of RST axons towards the 







pilot experiment (section 3.3.1) was quantified in the spinal cord horizontal 
sections at the level of the RST. A total of 3 to 4 sections per animal were 
analyzed and quantification was performed at 2 mm proximal to the lesion. 
The length of EGFP-labeled rubrospinal axons spreading on to the gray 
matter was measured using NeuronJ plug-in of ImageJ software (NIH, 
Maryland, USA) (Meijering et al., 2004). The quantification was normalized to 
the number of EGFP-labeled axons counted at 2 mm proximal to the lesion in 
each animal to avoid the transduction variation bias among the animals and 
the comparisons were done among all the groups. For the experimental set-
up evaluating gene therapy with AAV.BAG1, AAV.reggie1, AAV.miRNA-134 
and AAV.sh.ROCK2 (Table 3.3.3), the quantification of the axonal sprouting 
was performed in the spinal cord transverse sections at cervical (C2-C6) and 
thoracic levels (Th1-Th5) proximal to the lesion. Digital images were 
constructed using AxioVision MosaiX software (Zeiss, Göttingen, Germany) 
at 10 x magnification. An Axioplan microscope equipped with an Apotome 
module was used to visualize the axonal sprouting with higher magnification. 
A total of 5 sections covering each level of the sectioned spinal cord were 
used for the quantification. Axonal sprouting was quantified by counting the 
EGFP-positive axonal sprouts that extended from the RST bundle on to the 
gray matter at defined distances (Rexed's laminae V to VIII) until the central 
canal (Figure 28). In order to avoid bias by viral transduction variability 
among animals, an axonal sprouting index was determined by normalization 
of sprouts to the total EGFP-positive axon number counted at high cervical 
level (C2) in each animal. 
 
3.6.3 Quantification of lesion size and axonal degeneration 
Lesion quantification for the pilot experiment (section 3.3.1) was done in a 
total of 3 to 4 horizontal spinal cord sections counterstained with DAPI. We 
could not use an additional immunolabel for these sections against GFAP 
due to multiple native fluorescences derived from the AAV-tracing of the RST 
(with EGFP) and CST (with DsRed) and further immunostaining against 
GAP43 with Cy5-conjugated antibody. Therefore, we evaluated the lesion 







area indicating an accumulation of cells (glial or inflammatory cells) around 
the lesion in general. The lesion area was measured using ImageJ software 
(NIH, Maryland, USA). For lesion quantification in the experimental set-up of 
gene therapy with AAV.BAG1, AAV.reggie1, AAV.miRNA-134 and 
AAV.sh.ROCK2 (section 3.3.3) a total of 4 horizontal spinal cord sections at 
RST level (60 µm apart) were immunostained against GFAP to define the 
lesion area. Digital images were constructed using AxioVision MosaiX 
software or AxioVision PanoramaTM software (Axioplan, Zeiss, Göttingen). 
Areas with little or no GFAP immunoreactivity were defined as the lesion 
(Steward et al., 2003) and were measured using AxioVision LE software. 
Axonal degeneration was quantified at defined distances starting at the 
proximal lesion border to the EGFP-positive RST axon bundle. Again, the 
quantification was normalized to total EGFP-labeled RST axons in order to 
avoid bias due to viral transduction variability. 
 
3.7 Behavioral studies 
3.7.1 BBB - open field test 
All behavioral experiments were performed in a blinded fashion. BBB is one 
of the fundamental tests for the evaluation of spinal cord lesion models and it 
allows the analysis of various foot parameters with the score points from 0 to 
21 (“0” means no observable hind limb movements and “21” means the hind 
limb has consistent plantar stepping, coordination, toe clearance, trunk 
stability and parallel paw placement and the tail is always up). The motor 
behavior analysis for the BBB was performed according to (Basso et al., 
1995) where the animals were allowed to walk freely for 4 minutes in an open 
field box made of Plexiglas (75 x 30 cm). The observations of the foot 
parameters were scored manually for both hind limbs (RHL-lesioned and 
LHL-unlesioned). A basic score was taken before the SCI and after the SCI 
scores were collected at regular time points (Figure 7b & 10b). In general, 
BBB is a broad functional test for complete SCI models. In our test, being a 
partial lesion model, to increase the sensitivity of the BBB test, we assessed 
some specific foot parameters such as toe clearance, predominant paw 








3.7.2 Horizontal ladder rung test  
The ladder rung test is used to analyse the motor function both quantitatively 
and qualitatively (Metz and Whishaw, 2002, 2009). Initially, the rats were 
trained for two weeks to get used to walk on a 1 m horizontal ladder 
separated by metal rungs. After the training, a ladder rung test was 
performed for 13 weeks after the lesion and animals were videotaped with a 
fixed video camcorder (Figure 7b). Each animal was given 5 runs for each 
trial. From trial to trial, by varying the space between the rungs, the rung 
pattern was changed to prevent the animals from getting used to a certain 
rung pattern. The qualitative measurement by the foot fault scoring normally 
differentiates the placement of fore- and hind limbs in six different scores, but 
in the model which is used here, only the hind limbs (HL) were taken into 
account and only three scores were counted as miss steps: “Total miss” is 
defined as the hind limb falling between the rungs and leading to posture and 
balance disturbance of the animal, the “deep slip” is defined as the limb 
touching the rung but not holding the weight which causes a fall of the rat, 
and the “slight slip” is defined as a placing of the limb on the rung and 
slipping off but not resulting in a fall of the rat (Figure 15).  
 
All the video recordings were analysed and the missed steps were counted in 
a frame-by-frame slow motion. For statistical analysis, the error rate was 
counted in five runs per animal (errors/step) and the average calculated for 
the right hind limb (RHL, lesioned). The difference of the RHL score among 































Figure 15. Horizontal ladder rung test. Consecutive photographs 
illustrating the categories of foot falls: total miss, deep slip and slight slip 
during the ladder-rung walk. Image was modified from Metz and Whishaw, 
2002. 
 
3.7.3 CatWalkTM  gait analysis 
In order to evaluate the gait of the animals more precisely, a CatWalkTM 
analysis was performed using a CatWalkTM apparatus (Noldus, Weiningen, 
Netherlands) according to (Hamers et al., 2001). Before the SCI, all animals 
were trained for 2 weeks on every alternate day to run on the CatWalkTM 
apparatus. A basic score was taken once the animals were able to perform 3 
flawless runs on the walkway. Animals were allowed to run on the CatWalkTM 
glass floor (90 x 10 cm) and the refractions of the illuminated footprints on the 
glass floor were captured by a video camera below the runway. After the 
lesion, the score was assessed at regular time points (Figure 10b). The 
CatWalkTM XT9 Software was used for foot print classification and analysis of 
various parameters such as base of support, regularity index, print area and 









Multiple group comparisons were analyzed by one-way ANOVA followed by 
Tukey’s post-hoc test and two group comparisons were performed by an 
independent t-test. For comparing one variable with others within the group 
one-way ANOVA followed by Dunnett’s test was performed. All the statistics 
were performed using SPSS Statistics V.21 (IBM, Armonk, NY). Data are 
represented as mean ± SEM as indicated. Significances are indicated with 









4.1 Pilot project: Combination treatment with AAV.BAG1 and BPY-DCA 
for 16 weeks after dorsal spinal cord hemisection in rats 
4.1.1 Viral injections and spinal cord lesion  
To demonstrate sufficient transduction of the red nucleus, cortex and the 
respective RST and CST and to assure the expected extent of the lesion, 
animals were stereotactically injected with AAV vectors and three weeks later 
a dorsal spinal cord hemisection was performed at Th8. Additionally, animals 
were subjected to osmotic pump implantation immediately after lesion to 
apply the AST with BPY-DCA (Figure 7 and Table 6). The cortical injections 
with AAV.DsRed were used in this study to evaluate if any compensatory 
spontaneous axonal sprouting from CST towards the RST rostral to the SC 
lesion could be observed. Sixteen weeks after the dorsal hemisection the 
animals were perfused. Analysis of the EGFP and DsRed fluorophores 
expressed by the respective AAV vectors could visualize that the 
stereotactically injected AAV successfully transduced a defined area of the 
midbrain including the RN (Figure 16a) and the sensorimotor cortex (Figure 
16b) as well as the projecting axons in the contralateral RST (EGFP, green) 
and CST (DsRed, red) (Figure 16c&d). The ipsilateral RST was also partly 
labeled in addition to the contralateral (lesioned) RST as some of the RN 
axonal projections are known to descend ipsilaterally in the dorsolateral 
funiculus of the spinal cord (Küchler et al., 2002). Additionally, this could be 
correlated to a wider spread of the virus around the injection site in the RN in 
some animals. The right dorsal hemisection resulted in a complete 
transection of the RST and CST (Figure 16d).   
In the pilot project, several animals were found to have severe foot lesions 
due to autophagy and licking of the toes of the non-lesioned hind limb. This 
self-mutilating behavior was reported in rodents after experimental spinal 
cord lesions and could be due to a dysfunction of the gamma-aminobutyric 
acid class B (GABA-B) system and affection of sensory inputs after the spinal 
cord lesion (Rahimi-Movaghar; Yezierski, 1996; Zhang et al., 2001). Animals 







topical antiseptic wound spray and with Meloxidyl were sacrificed and 
excluded from the study. In addition to this, some AAV injections in the RN 
were not successful and the injections were found to be above the RN and 
failed to label the RN and subsequently the RST. These animals with very 
low or no RST transductions were also eliminated from the study (see 
section 3.3.1). Due to the low number of remaining animals a statistical 










Figure 16. Experimental paradigm for combination treatment with 
AAV.BAG1 and AST. (a) Representative coronal brain section showing 
AAV-mediated EGFP-expression (green) at 16 weeks after AAV injection to 
the ipsilateral RN. Scale bar 1000 µm. (b) Representative coronal brain 
section showing AAV-mediated DsRed-expression (red) at 3 weeks after 
AAV injection to the ipsilateral sensorimotor cortex. Scale bar 1000 µm. (c) 
Representative transverse spinal cord section showing anterograde labeling 
of RST by AAV-mediated EGFP expression and CST by AAV-mediated 
DsRed-expression. (d) Representative longitudinal spinal cord section 
showing anterograde labeling of RST by AAV-mediated EGFP-expression 
and CST by AAV-mediated DsRed-expression and DAPI (blue). White 
dashed lines mark the lesion. Scale bar 500 µm. AAV= adeno-associated 
virus; RN= red nucleus; CX= cortex; RST= rubrospinal tract; SCI=spinal cord 








4.1.2 Effect of combination treatment with AAV.BAG1 and AST on 
axonal sprouting at 16 weeks after dorsal spinal cord hemisection 
We addressed the question if the anti-scarring treatment (AST) with BPY-
DCA in combination with the anti-apoptotic treatment with AAV.BAG1 would 
be beneficial for axonal regeneration, sprouting and functional motor 
behavior after SCI. The experiment was performed as described in section 
4.1.1. For quantification of axonal sprouting, a total of 3 to 4 horizontal spinal 
cord sections per animal at the level of RST and CST were analyzed. EGFP-
labeled axonal sprouts extending into the gray matter of the spinal cord 2 mm 
rostral to the SC lesion were identified (Figure 17a) and the length of the 
axonal sprouts was measured using NeuronJ plug in of ImageJ software 
(NIH, Maryland, USA) (Meijering et al., 2004). Axonal sprouting was 
normalized to the number of EGFP-positive axons in each animal to avoid a 
bias due to variations in the transduction efficiencies among the animals. We 
found a trend to more axonal sprouting in the AAV.BAG1 treated groups 
either alone or in combination with the anti-scarring treatment (AST) or anti-
scarring buffer (ASB) (Figure 17b). Anti-scarring treatment alone did not 
show much influence on the axonal sprouting and we did not find any CST 
axons sprouting caudal to the lesion. The CTB injections in the RN were 
unable to label the regenerating RST axons after the SC lesion. We found 
that the distribution of the CTB tracer was minimal in the brain tissue and 
possibly the atrophied RN neurons were unable to take up the dye after the 
lesion. We also immunolabeled the spinal cord sections against GAP-43 to 
visualize any regenerating axons. However, the GAP-43 staining appeared 
rather unspecific and we could not identify any regenerating axons (Figure 
18). Taking this outcome into consideration, GAP-43 immunolabeling was not 
considered useful for our quantifications of sprouting or axonal regeneration. 
Due to the limitations in animal numbers caused by foot lesions and 
unsuccessful RN injections, we could not draw robust statistical conclusions 
about the combination of AAV.BAG1 and AST with BPY-DCA in this 









Figure 17. Effect of combination treatment with AAV.BAG1 and AST on 
axonal sprouting 16 weeks after dorsal spinal cord hemisection. (a) 
Representative longitudinal section of the spinal cord depicting the model of 
axonal sprouting quantification and anterograde labeling of RST with AAV-
EGFP (green) and CST with AAV.DsRed (red) and DAPI (blue). White 
dashed lines mark the lesion. Square white boxes represent the areas used 
for quantification of axonal sprouting 2 mm rostral to the lesion. The higher 
magnification of one square (marked with a star) is shown as fluorescent and 
grayscale image (for quantification in ImageJ). Scale bar horizontal spinal 
cord 500 µm; higher magnification image, 100 μm. (b) Axonal sprouting 
quantification. Bars represent the means ± SEM. AAV.BAG1, n=3; 
AAV.EGFP, n=2; AAV.BAG1+AST, n=2; AAV.EGFP+AST, n=1; 









In this experiment, the AAV.BAG1 treatment showed a clear trend towards 
more axonal sprouting compared to other treatments in spite of the limited 
number of animals. In addition to this, the need for a better anterograde-
tracing agent for the tracking of axonal regeneration after spinal cord lesion 
was noted for further experiments.  
 
 
Figure 18. GAP-43 immunolabeling for visualization of regenerating 
RST axons at 16 weeks after dorsal spinal cord hemisection. 
Representative longitudinal section of the spinal cord with GAP-43 labeling 
(Cy5). The corresponding binary image (arrow) depicts the dark lines (axons) 
immunolabeled for GAP-43, but a massive unspecific staining is also 
observed. A clear identification of regenerating axons therefore was not 
considered feasible on the basis of this staining result.  
 
4.1.3 Osmotic mini-pump implantation resulted in increased lesion size 
at 16 weeks after dorsal spinal cord hemisection 
Osmotic mini-pumps were used to deliver the antiscaring treatment (BPY-
DCA or TRIS buffer as control) continuously at a controlled speed and over a 
specific time period. This osmotic pump implantation was reported to be safe 
in several other models (Doucette et al., 2000; Verma et al., 2004). As this 
osmotic mini-pump was used for the first time in our experimental paradigm, 







A total of 3 to 4 spinal cord horizontal sections per animal were subjected to 
a DAPI counter stain for nuclear staining. Due to multiple native colors from 
the AAV tracing of the RST (EGFP) and CST (DsRed) and further 
immunostaining of GAP-43 with Cy5 conjugated antibody, we could not 
additionally stain the sections with GFAP for determination of lesion size. 
Therefore, in this pilot experiment the lesion quantification was performed 
based on tissue morphology and DAPI staining. The area of 1 cm around the 
lesion was photographed with AxioVision PanoramaTM software (Axioplan, 
Zeiss, Göttingen). The lesion area was then quantified with ImageJ software 
(NIH, Maryland, USA). We found that the animals implanted with the osmotic 
mini-pump (AAV.BAG1+AST, AAV.EGFP+AST, AAV.BAG1+ASB & 
AAV.EGFP+ASB) had a bigger lesion size (2 to 5 fold) compared to the 
animals without pump implantation (AAV.BAG1 and AAV.EGFP) independent 
of the applied pharmacological treatment (Figure 19a &19b).  A similar effect 
had been reported in mice with brain infusions using osmotic mini-pump 
implantation (Jabłońska et al., 1993). Formation of scar tissue around the 
catheter of the osmotic mini pump was observed at the lesion site, which 
might lead to larger lesion sizes in our experimental paradigm.  
 
This data shows that in this experimental paradigm the implantation of 
osmotic mini-pumps led to an increased lesion size compared to the animal 
groups without pump implantations. Therefore, the mini-pump paradigm 
appears not suitable for the analysis of therapeutic drug effects in this 










Figure 19. Effects of osmotic mini-pump implantation on lesion size at 
16 weeks after dorsal spinal cord hemisection. (a) Representative 
photomicrographs of longitudinal SC sections of animals treated with 
AAV.BAG1, AAV.EGFP, AAV.BAG1+AST, AAV.EGFP+AST, 
AAV.BAG1+ASB, AAV.EGFP+ASB. The red highlighted area represents the 
lesion. Scale bar 500 μm.  (b) Lesion size quantification. Bars represent the 
means ± SEM. AAV.BAG1, n=3; AAV.EGFP, n=2; AAV.BAG1+AST, n=2; 








4.1.4 Effect of combination treatment with AAV.BAG1 and AST on motor 
behavior at 16 weeks after dorsal spinal cord hemisection. 
 
4.1.4.1 BBB 
In order to investigate the effect of combination treatment with AAV.BAG1 
and AST (BPY-DCA) on motor recovery, a BBB test was done according to 
(Basso et al., 1995). The animals were allowed to walk in an open field for 4 
minutes and the basic score was taken. The score was obtained every 
alternate week up to 13 weeks after the spinal cord lesion (Figure 7b). At the 
basic level, all the animals scored a total 21-point BBB score. The score was 
not different among the groups even after the viral injections, indicating that 
the viral injections did not have a negative effect on the motor behavior. At 
week 1 after right dorsal spinal cord hemisection the score went down to 13 
in all groups indicating a successful partial lesion. Over time, the score 
improved up to 18 by 13 weeks in all groups, but no significant differences 
among the groups in the BBB total score were observed (Figure 20a). 
 
4.1.4.2 Horizontal ladder rung test 
The horizontal ladder rung test was used to qualitatively and quantitatively 
analyze the gait of rats after dorsal spinal cord hemisection. Rats were 
trained for 2 weeks on the ladder rung before the basic score was taken. 
After the spinal cord lesion, a score was taken at week 1 which was followed 
up to week 13 (Figure 7b). All tests were videotaped and analyzed manually 
with a frame-by-frame analysis. An average of 5 runs was taken for each test 
per animal and the missed steps were quantified for the affected right hind 
limb (RHL). All the rats were able to cross the ladder rung without any errors 
before SCI but one week after SCI, significant errors were noted for the RHL. 
Over the weeks, the number of missed steps and errors was reduced, but no 












Figure 20. Effect of combination treatment with AAV.BAG1 and AST on 
motor behavior at 16 weeks after dorsal spinal cord hemisection. (a) 
Quantification of BBB total score (21 point scale) of the right hind limb 
measured before the lesion and 1, 3, 5, 7, 9, 11 & 13 weeks after RST lesion. 
(b) Quantification of horizontal ladder rung test score as average of miss 
steps of the right hind limb measured before the lesion and 1, 3, 5, 7 & 13 
weeks after RST lesion. Bars represents the means ± SEM. AAV.BAG1, n=3; 
AAV.EGFP, n=2; AAV.BAG1+AST, n=2; AAV.EGFP+AST, n=1; 
AAV.BAG1+ASB, n=2; AAV.EGFP+ASB, n=1. 
 
 
Taken together, both BBB and horizontal ladder rung test did not show any 
significant differences in motor skill improvement in any of the treatment 








4.2 Anterograde tracing of RST after dorsal spinal cord hemisection 
4.2.1 Anterograde tracing of the RST with AAV.EGFP before and BDA or 
AAV.DsRed after the right dorsal spinal cord hemisection 
 
As described in the results section of our pilot experiments, no regenerating 
rubrospinal axons after the spinal cord lesion using CTB labeling could be 
identified. Therefore we investigated other anterograde tracing methods in 
two different sets of experiments (Table 7 & 8, Figure 8 & 9). In the first set 
of experiments (Table 7 & Figure 8), the animals were first injected into the 
RN with AAV.EGFP to trace the RST. After week 3 (to allow for sufficient 
AAV transduction and transgene expression), the animals were subjected to 
right dorsal spinal cord hemisection. Another 3 weeks after the dorsal 
hemisection of the spinal cord, a second injection into the RN was performed 
with BDA or AAV.DsRed to specifically label the rubrospinal axons after the 
lesion. Four weeks after the second RN injection, animals were perfused and 
the spinal cord and the brain sections were analyzed for BDA, EGFP and 
DsRed transduction. The first stereotactic RN injections with AAV.EGFP 
could sufficiently transduce the RN in the midbrain and subsequently its 
axonal projections in the RST running contralaterally in the spinal cord. 
Interestingly, the second stereotactic RN injection with BDA could be seen in 
the RN, while we could not detect a labeling of the RST even at high cervical 
levels (Figure 21). The second injection with AAV.DsRed on the other hand, 
did label RN neurons and a few axonal projections of the RST in the 
contralateral SC at the cranial and cervical levels but did not sufficiently label 










Figure 21. Anterograde tracing of the RST with AAV.EGFP before and 
BDA after dorsal spinal cord hemisection, respectively. (a) 
Representative coronal midbrain section showing RN injection with AAV-
mediated EGFP-expression (green) and BDA (pink). AAV.EGFP was injected 
before and BDA after dorsal hemisection, respectively. Scale bar 1000 µm. 
RN=red nucleus, Aq=Aqueduct. (b) Representative transverse cervical spinal 
cord section showing RST tracing with EGFP (green) and BDA (pink). Scale 
bar 200 µm. Corresponding photomicrographs c, d & e show a higher 











Figure 22. Anterograde tracing of RST with AAV.EGFP and AAV.DsRed 
before and after dorsal spinal cord hemisection, respectively. 
Representative coronal midbrain section showing RN injection with AAV- 
EGFP (green) before and AAV.DsRed (red) after dorsal hemisection, 
respectively. The green line depicts the path of the RST (white oval shape) 
visualized with EGFP at C2, C5, Th1 and Th5 proximal to the lesion.  The 
RST is additionally stained by AAV.DsRed (dotted blue square of the 
corresponding spinal level) shown in higher magnification, where the red line 
narrates the path of RST at 3 weeks after dorsal hemisection. RN= red 
nucleus; RST= rubrospinal tract; C2 & C5= cervical level 2, 5; Th1 & Th5= 







4.2.2 Anterograde tracing of RST immediately after dorsal spinal cord 
hemisection with AAV.EGFP  
In search for a better labeling technique and considering a rapid and 
significant RN neuronal atrophy following SCI, we investigated the possibility 
of AAV-mediated labeling immediately following the SCI. In the second set of 
experiments (Table 8 and Figure 9), the animals were therefore first 
subjected to a dorsal spinal cord hemisection and this was immediately 
followed by stereotactic RN injections with AAV.EGFP. After 4 weeks, the 
animals were perfused. In 
this paradigm the AAV 
vector could successfully 
label the RN and 
subsequently trace the RST 
both at cervical and thoracic 
levels until the lesion at Th8 
(Figure 23). 
 
Figure 23. Anterograde 
tracing of RST 
immediately after dorsal 
spinal cord hemisection. 
Representative coronal 
midbrain section showing RN 
injection with AAV-mediated 
EGFP-expression (green), 
immunolabeling with NeuN 
(red). The green line depicts 
the path of the RST (white 
ovals) labeled with EGFP at 
the level of the medulla, C5, 
Th1 and Th5 proximal to the 
lesion. The dotted pink square 
at Th5 is shown at a higher 
magnification. RN= red 
nucleus; RST= rubrospinal 
tract; C5= cervical level 5; Th1 








These anterograde tracing results were now used for the second 
experimental paradigm (Figure 9a), where the animals were subjected to 
dorsal spinal cord hemisection followed by immediate RN AAV-injections. It 
has to be noted, however, that in this paradigm AAV-vector-mediated tracing 
of RST took place at a time, where axonal degeneration was just initiated by 
SCI. However, this paradigm allowed us to clearly identify regenerative 
changes following lesion, because all axons visualized in this paradigm have 
obtained their label after spinal cord hemisection. 
 
4.3 Gene therapy with AAV.BAG1, AAV.reggie1, AAV.miRNA-134, and 
AAV.sh.ROCK2 at 12 weeks after dorsal spinal cord hemisection 
4.3.1 Experimental set up for gene therapy with AAV.BAG1, 
AAV.reggie1, AAV.miRNA-134, and AAV.sh.ROCK2 at 12 weeks after 
dorsal spinal cord hemisection 
To demonstrate sufficient transduction of the RN and the RST after 
stereotactic injections with AAV vectors and to assure the expected extent of 
the lesion, preliminary experiments were performed. Animals were subjected 
to right dorsal spinal cord hemisection at Th8 followed by immediate 
stereotactic AAV injection in the left RN (Figure 24a). Three weeks after AAV 
injection the animals were perfused. Co-expression of EGFP in all AAV 
vectors could visualize that the stereotactic viral injections successfully 
transduced a defined area of the midbrain including the RN (Figure 24b) and 
projecting axons in the contralateral RST (Figure 24d). The right dorsal SC 
hemisection resulted in a complete transection of the RST (Figure 24d). 
Acute right dorsal hemisection of the RST (3 days after the RST lesion) also 
resulted complete transection of RST (Figure 24c). We confirmed over-
expression of BAG1 and down-regulation of ROCK2 in the RN after viral 
injections by immunohistochemical analyses of midbrain sections (Figure 










Figure 24. Experimental paradigm for AAV.BAG1 and AAV.sh.ROCK2 
gene therapy. (a) Representative coronal brain section showing AAV-
mediated EGFP-expression (green) at 3 weeks after AAV injection to the 
ipsilateral RN. Immunolabeling for NeuN (red), DAPI (blue). Scale bar 1000 
µm. (b) Representative transverse spinal cord section showing the dorsal 
hemisection at three days after lesion. Immunolabeling for GFAP (red), DAPI 
(blue). White dashed lines mark the lesioned area after hemisection, arrow 
points to the rubrospinal tract. Scale bar 200 µm. (c) Representative 
longitudinal section of the spinal cord showing the anterograde labeling of 
RST by AAV-mediated EGFP-expression (arrow). Immunolabeling for GFAP 
(red), DAPI (blue). White dashed lines mark the lesion. Scale bar 500 µm. 
AAV=adeno-associated virus; RN=red nucleus; RST=rubrospinal tract; 











Figure 25. Regulation of BAG1 and ROCK2 expression in the RN by 
AAV vectors. (a) Representative photomicrographs showing AAV.BAG1-
transduced RN neurons (EGFP; green), immunolabeling for BAG1 (Cy3; red) 
and NeuN (Cy5; white). The injected (upper panel) and uninjected (lower 
panel) sides of the midbrain are shown 12 weeks after dorsal hemisection. 
(b) Representative photomicrographs showing AAV.sh.ROCK2-transduced 
RN neurons (EGFP; green), immunolabeling for ROCK2 (Cy3; red) and 
NeuN (Cy5; white).  The injected (upper panel) and uninjected (lower panel) 
sides of the midbrain are shown 12 weeks after dorsal hemisection. The 
white arrows point to ROCK2 expressing neurons (cytoplasmic red puncta). 
Scale bars: 10 μm.  
 
4.3.2 Effect of AAV.reggie1 and AAV.miRNA-134 on the red nucleus 
after dorsal spinal cord hemisection 
In contrast to animals injected with AAV.BAG1, AAV.EGFP, AAV.sh.ROCK2 
or AAV.sh.firefly the expression levels of EGFP were found to be very weak 
for animals injected with AAV.reggie1. In addition, staining with NeuN 
suggested a toxic effect of AAV.reggie1 expression as the number of 
surviving RN neurons was reduced (Figure 26d).   
Similarly, EGFP expression levels in the RN in AAV.miRNA-134-injected 







immunostaining also indicated loss of neuronal numbers by 12 weeks after 
the lesion, suggesting toxic effects of the vector (Figure 26c).  
 
 
Figure 26. RN transduction by AAV.miRNA-134 and AAV.reggie1. (a) 
Scheme of a coronal midbrain section showing an overview of the areas 
depicted in b and c. The needle tract for stereotactic AAV injections is 
marked. The area surrounded by the dashed line red box is shown in the RN 
overview in b and c.  Red nucleus (RN), aqueduct (Aq), nucleus of 
oculomotor nerve (OMN), substantia nigra (SN). Scale bars 1000 μm (b, c) 
Representative photomicrographs of the midbrain (RN overview) of animals 
injected with AAV.miRNA-134 (b) and AAV.reggie1 (c). Higher magnification 
images for the RN labeled by EGFP (green), NeuN (red) and DAPI (blue) at 
12 weeks after dorsal spinal hemisection. Scale bars 1000 μm (RN 
overview), 500 μm (higher magnification of RN). 
 
Due to these obvious toxic effects in the RN by both AAV.reggie1 and 








4.3.3 AAV.BAG1 and AAV.sh.ROCK2 improve survival of RN neurons 12 
weeks after dorsal spinal cord hemisection 
It has been shown previously that RN neurons degenerate or undergo severe 
atrophy following RST lesion and this could represent a handicap for 
regeneration (Kwon et al., 2002a; Tseng et al., 1996). In order to evaluate the 
neuroprotective effects of AAV.BAG1 and AAV.sh.ROCK2 on RN neurons 12 
weeks after RST lesion, midbrain sections at the level of the RN were 
immunolabeled with antibodies against NeuN. NeuN quantifications were 
performed both in the injected RN (corresponding to the lesioned RST) and 
un-injected (corresponding to the unlesioned RST) which served as an 
internal control for each animal. In all experimental approaches, we 
compared each AAV vector with its appropriate control only, e.g. AAV.BAG1 
vs. AAV.EGFP (both vectors overexpressing a protein of interest) and 
AAV.sh.ROCK2 vs. AAV.sh.firefly (both vectors expressing a functional 
shRNA). The number of NeuN-positive cells in the RN was significantly 
increased in the groups transduced with AAV.BAG1 compared to AAV.EGFP 
(173.0 ± 7.0 vs. 80.7 ± 11.0 NeuN-positive cells per section). Animals 
injected with AAV.sh.ROCK2 also showed significantly higher numbers of 
NeuN-positive neurons in the RN as compared to AAV.sh.firefly-treated 
controls (85.5 ± 6.3 vs. 51.2 ± 3.2 NeuN-positive cells per section). The 
numbers of NeuN-positive cells in the contralateral uninjected RN did not 
differ among the groups (Figure 27b & c).  
 
As severe atrophy was reported for the RN neurons after the RST lesion 
(Ruitenberg et al., 2004),(Kwon et al., 2004), we performed a quantification of 
RN neuron soma size. Most of the neuronal cell bodies in the AAV.EGFP-
injected animals had sizes of less than 300 µm2 and there were none, which 
were larger than 600 µm2. In contrast AAV.BAG1-injected animals showed a 
larger spectrum of soma sizes with more than 20% of the RN cell bodies 
being larger than 600 µm2. Differences were less pronounced among the 
AAV.shRNA-injected animals. However, AAV.sh.ROCK2-injected animals 
showed more larger-sized cell bodies than AAV.shRNA-firefly-injected 







were larger compared to the injected RN side for AAV.EGFP, 
AAV.sh.ROCK2 and AAV.sh.firefly groups while soma sizes were similar to 
the uninjected side in the AAV.BAG1-treated group (Figure 27b). 
 
Overall, this data demonstrates that AAV.BAG1 improved neuronal survival 
and reversed the lesion-induced atrophy of the RN neurons after RST lesion. 
AAV.sh.ROCK2 had also improved the survival of RN neurons and partially 
improved the atrophy of RN neurons compared to its control. In general, 
neuronal numbers in AAV.shRNA-injected animals were lower than in 
animals injected with AAV over expressing a protein. This is likely to be 
attributed to vector-inherent toxicity due to chronic shRNA-expression and 










Figure 27. Neuronal 
survival in the RN after 
AAV.BAG1 and 
AAV.sh.ROCK2 gene 
therapy 12 weeks after 
lesion. (a) Scheme of a 
coronal brain section 
showing an overview of 
the areas depicted in b: 
red nucleus (RN), 
aqueduct (Aq), nucleus 
of oculomotor nerve 
(OMN), substantia nigra 
(SN). The needle tract for 
stereotactic AAV 
injections is marked. The 
area surrounded by the 
dashed line red box is 
shown in the RN 
overview in b. (b) 
Representative 
photomicrographs of the 
midbrain (RN overview; 
middle panel) and of both 
injected (left panel) and 
uninjected RN (right 
panel) in higher 
magnification for all AAV-
vectors used in this 
study. AAV-mediated 
EGFP-expression 
(green) delineates the 
transduced area. 
Immunolabeling for 
NeuN (red), DAPI (blue). 
Scale bars 1000 μm (RN 
overview), 500 μm 
(injected RN, uninjected 
RN). (c) Quantification of 
NeuN-positive cells in the 
injected (lesioned RST) 
and uninjected 
(unlesioned RST) RN. 
(d) Quantification of the 
area of the neuronal 
somata in the RN of the 
AAV-injected side. Bars 
in c and d represent 
means ± SEM. 
Differences were 
considered significant 
with * p<0.05; ** p<0.01; 
*** p<0.001. AAV.EGFP, 











4.3.4 Axonal sprouting at cervical SC is enhanced by treatment with 
AAV. BAG1 and AAV.sh.ROCK2  
To investigate the effects of AAV.BAG1 and AAV.sh.ROCK2 gene therapies 
on collateral sprouting, proximal to the lesion at the cervical level, animals 
were perfused 12 weeks after dorsal spinal cord hemisection and AAV 
injection. A total of 5 transverse cryosections of the cervical SC were used at 
the level of C2-C6. In order to assess the distribution of RST sprouts towards 
the Rexed's laminae V and VI and towards the dorsal part of lamina VII 
(Küchler et al., 2002) after the lesion, the number of EGFP-labeled axonal 
sprouts were counted at defined distances from RST to the central canal 
(Figure. 28a & 28b). The number of sprouts was normalized to EGFP-
transduction to avoid bias by the individual variability of transduction 
efficiency between different animals. A significant increase in axonal 
sprouting (up to 2-fold) was observed with AAV.BAG1 vs. AAV.EGFP and 
this effect was especially pronounced at distances of 800–1200 µm from the 
RST. The effect of AAV.sh.ROCK2 appeared even more pronounced, since 
AAV.sh.firefly control-injected animals showed a minor sprouting response 
(Figure 29 b & 29c). We observed that the extent of sprouting was 
dependent on the spinal cord levels and mostly pronounced in cranially 
investigated level C2.  Axonal sprouting decreased towards more caudally 
located levels with the lowest values at C6 (Figure 30) and this trend was 
similarly observed in all treatment groups. In addition to this, we also 
observed that the axonal sprouts of the RST co-localize with synaptophysin 
in the close vicinity of interneurons of Rexed's laminae V and VI in the 
cervical SC. This suggests that the establishment of synaptic contacts onto 
interneuron’s by the RST sprouts and the density of such synaptic contacts 










Figure 28. Model of axonal sprouting quantification at the cervical and 
thoracic levels. Scheme of axonal sprouting quantification of the transverse 
cervical (a) and thoracic (b) spinal cord depicting the location of RST axons 
(green), Rexed’s laminae of the spinal cord gray matter (pink lines) and the 












Figure 29. Axonal 
sprouting in the 
cervical SC after 
AAV.BAG1 and 
AAV.sh.ROCK2 
gene therapy at 12 
weeks after lesion. 




location of the 
micrographs 
(squares) shown in 
b. Rexed’s laminae  
(I-IX) of the spinal 
cord gray matter 





cervical spinal cord 
sections of animals, 
which have been 





Axonal sprouting to 
the gray matter is 
visualized by AAV-mediated EGFP  
expression (green), DAPI (blue). Overview and higher magnifications of 
dorsal, ventral and central areas (see a) are shown. Scale bars: 1000 μm 
(overview), 50 μm (dorsal, ventral and central). (c) Quantification of axonal 
sprouting in the cervical spinal cord (C2-C6) at different distances from the 
RST normalized to RST transduction efficiency (EGFP-positive axons 
counted at C2). Bars represent the means ±SEM. Differences were 
considered significant with *p<0.05; **p<0.01; ***p<0.001. AAV.EGFP, n=4; 










Figure 30. Effect of AAV.BAG1 and AAV.sh.ROCK2 gene therapy on 
Axonal sprouting at the cervical levels 2 to 6 at 12 weeks after lesion. 
(a) Scheme of the transverse cervical spinal cord depicting the location of 
RST and Rexed’s laminae (I-IX) of the spinal cord gray matter marked for the 
orientation. (b) Representative photomicrographs of transverse cervical 
spinal cord sections C2 to C6 of animals, which have been injected in the RN 
with AAV.EGFP, AAV.BAG1, AAV.sh.firefly and AAV.sh.ROCK2. Axonal 
sprouting to the gray matter is visualized by AAV-mediated EGFP expression 
(green), DAPI (blue). Scale bar 1000 μm. (c) Quantification of differences in 
axonal sprouting among the cervical spinal cord levels (C2 to C6) normalized 
to RST transduction efficiency (EGFP positive axons counted at C2) 12 
weeks after RST lesion. Bars represent the mean ±SEM. Differences were 
considered significant with *p<0.05; **p<0.01; ***p<0.001. AAV.EGFP, n=4; 









Figure 31. RST sprouts establish contacts with interneurons in the gray 
matter Rexed’s laminae of the cervical spinal cord. Representative 
photomicrographs of transverse cervical spinal cord sections of animals, 
which have been injected in the RN with AAV.EGFP, AAV.BAG1, 
AAV.sh.firefly and AAV.sh.ROCK2. Axonal sprouting to the gray matter is 
visualized by AAV-mediated EGFP expression (green), immunolabeling of 
NeuN (Cy5), synaptophysin (red) and DAPI (blue) and the colocalization of 
axonal sprouts with synaptophysin and contacts with NeuN (black arrows) in 









4.3.5 Axonal sprouting at thoracic SC is enhanced by treatment with 
AAV. BAG1 and AAV.sh.ROCK2  
A similar quantification that was obtained at the cervical SC for axonal 
sprouting was also performed at the thoracic level, i.e. closer to the lesion, 
but at a larger distance to the affected neuronal somata of the RN. Here, a 
total of 5 transverse sections of the spinal cord at the levels of Th1-Th5 were 
examined. Similar to the cervical SC, AAV.BAG1 resulted in stronger axonal 
sprouting than AVV.EGFP at the thoracic level, although this difference was 
not significant. In contrast, AAV.sh.ROCK2 significantly improved axonal 
sprouting as compared to AAV.sh.firefly group. The highest number of 
sprouting fibers was observed at a distance of 600 – 800 µm from the RST 
(Figure 32). Consistent to our findings at cervical level, we observed stronger 
sprouting more at cranial levels than at caudal ones (Figure 33). In general, 
levels of sprouting at cervical spinal cord were more pronounced than at 
thoracic levels (Figure 33). Taken together, AAV-mediated overexpression of 
BAG1 as well as shRNA-mediated downregulation of ROCK2 strongly 
increased sprouting at cervical and thoracic levels following RST lesion and 
this sprouting response was inversely correlated with the distance to the 







Figure 32. Axonal 
sprouting in the 
thoracic SC after 
AAV-gene therapy 
at 12 weeks after 
lesion. (a) Scheme of 
a transverse thoracic 
SC section depicting 
the location of the 
micrographs 
(squares) shown in b. 
Rexed’s laminae  (I-
IX) of the spinal cord 






spinal cord sections 
of animals, which 
have been injected in 





Axonal sprouting to 





Overview and higher 
magnifications of 
dorsal, ventral and central areas (see a) are shown. Scale bars: 1000 μm 
(overview), 50 μm (dorsal, ventral and central). (c) Quantification of axonal 
sprouting in the thoracic spinal cord (Th1-Th5) at different distances from the 
RST normalized to RST transduction efficiency (EGFP-positive axons 
counted at C2). Bars represent the means ±SEM. Differences were 
considered significant with *p<0.05; ***p<0.001. AAV.EGFP, n=4; 










Figure 33. Effect of 
AAV.BAG1 and 
AAV.sh.ROCK2 
gene therapy on 
Axonal sprouting at 
the thoracic levels 1 
to 5 at 12 weeks 
after lesion. (a) 
Scheme of the 
transverse thoracic 
spinal cord depicting 
the location of RST 
and Rexed’s laminae 
(I-IX) of the spinal 
cord gray matter 





spinal cord sections 
Th1 to Th5 of 
animals, which have 
been injected in the 
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DAPI (blue). Scale 
bar 1000 μm. (c) 
Quantification of 
differences in axonal 
sprouting among the 
thoracic spinal cord 
levels (Th1 to Th5) normalized to RST transduction efficiency (EGFP positive 
axons counted at C2) 12 weeks after RST lesion. (d) Axonal sprouting 
quantification comparison between cervical and thoracic spinal cord 12 







considered significant with *p<0.05; **p<0.01; ***p<0.001. AAV.EGFP, n=4; 
AAV.BAG1, n=8, AAV.sh.firefly, n=7 & AAV.sh.ROCK2, n=8. 
 
4.3.6 Effects of AAV.BAG1 and AAV.sh.ROCK2 on lesion size and 
axonal degeneration  
Since lesion size has a strong influence on functional outcome, we quantified 
the lesion size to exclude any effects of extent of the lesion on AAV gene 
therapy outcome. For this, horizontal sections of the spinal cord at RST level 
were immune-labeled with antibodies against GFAP and the lesion area was 
defined in the absence of GFAP immunostaining. However, no significant 
differences were observed between treatment groups in regard to the lesion 
size (Figure 34r). On the other hand stabilization of lesioned axons has been 
shown to be beneficial for axonal regeneration (Hellal et al., 2011). We  thus 
assessed the impact of gene therapy on lesion-induced axonal degeneration 
by quantification of the EGFP-labeled RST axons at different distances from 
the proximal lesion border. Animals treated with AAV.BAG1 showed more 
EGFP-positive axons at all distances from the lesion than AAV.EGFP-treated 
animals, which was significant at 100 – 200 µm (Figure 34a-d, e-h & q). 
More axons were stabilized in the AAV.sh.ROCK2-treated group compared 
to the control AAV.sh.firefly group. However, this observation was not 
statistically significant (Figure 34 i-l, m & q). No EGFP-positive fibers 








Figure 34. Effects of 
AAV.BAG1 and 
AAV.sh.ROCK2 gene 
therapy on lesion size 
and axonal degeneration 




longitudinal SC sections of 
animals injected with 
AAV.EGFP (a-d), 
AAV.BAG1 (e-h), 
AAV.sh.firefly (i-l) and 
AAV.sh.ROCK2 (m-p) into 
the RN. Overviews (a, e, i, 
m) and higher 
magnification insets (b-d, f-
h, j-l, n-p) show AAV-
mediated expression of 
EGFP in the rubrospinal 
axons proximal to the 
lesion. Immunolabeling for 
GFAP (red). Scale bars 
500 μm (a, e, i, m) and 100 
μm (b-d, f-h, j-l, n-p). (q) 
Quantification of RST axon 
degeneration. Axonal 
profiles counted a different 
distances proximal to the 
lesion and normalized to 
transduction (EGFP 
positive axons counted at 
C2). (r) Lesion size 
quantification. The GFAP-
negative area was taken as 
lesion area. Bars represent 
the means ±SEM. 
Differences were 
considered significant with 
*p<0.05. AAV.EGFP, n=4;  
AAV.BAG1, n=8,  










4.3.7 Effect of AAV.BAG1 and AAV.sh.ROCK2 on motor recovery  
Quantification of neuronal survival, axonal degeneration, sprouting and lesion 
size precisely characterize effects of AAV gene therapy on a histological level 
and may suggest subclinical effects by AAV-mediated gene therapy.  
Functional outcome, however, is of strong clinical relevance and therefore 
motor function was assessed with the BBB open field test and the CatWalkTM 
analysis at week 1, 3, 7 and 11 following the lesion (Basso et al., 1995). All 
the animals scored a complete score (21 points) in the open field test before 
the lesion. However, one week after the lesion, the score was reduced to 13 
± 1 in all groups and over the course of 11 weeks animals showed an 
improved motor function with an increased score of 15 ± 1. AAV.BAG1-
treated animals showed a significant improvement at week 11 compared to 
week 1, while this was not observed for groups treated with AAV.EGFP, 
AAV.sh.firefly or AAV.sh.ROCK2. There was no significant difference in the 
direct comparison of treatment groups and their appropriate controls 
(AAV.BAG1 vs. AAV.EGFP and AAV.sh.firefly vs. AAV.sh.ROCK2) (Figure 
35a). Since this model is a partial lesion model additional and more subtle 
motor parameters such as paw placement, toe clearance and trunk stability 
were assessed as a sub score to identify smaller differences. At week one 
after the lesion all groups showed a marked reduction in the score with no 
significant differences between AAV.BAG1 and AAV.EGFP, while the score 
for AAV.sh.ROCK2 was significantly higher than for AAV.sh.firefly. However, 
only the AAV.BAG1-treated group showed a significantly increased score as 
compared to AAV.EGFP at the final quantification at week 11 (4.5 ± 0.32 vs. 
3 ± 0.70 points). Animals treated with AAV.sh.ROCK2 showed a trend 
towards a higher score in comparison to their appropriate control 
AAV.sh.firefly (Figure 35b). A more detailed gait analysis was also 
performed using the CatWalkTM system, which showed significant differences 
between AAV.sh.firefly and AAV.sh.ROCK2 groups at week 1, however there 
were no significant differences between the treatment groups at later time 











Figure 35. Effect of AAV.BAG1 and AAV.shROCK2 gene therapy on 
motor behavior quantified by BBB. (a) BBB total score (21 point scale) of 
the right hind limbmeasured before the lesion and 1, 3, 7 & 11 weeks after 
RST lesion. (b) BBB sub score quantification of the right hind limb, 
considering the parameters toe clearance, predominant paw position and 
trunk instability. Bars represent the means ± SEM. Differences were 
considered significant with *p<0.05. AAV.EGFP, n=4; AAV.BAG1, n=8, 


















Figure 36. Effect of AAV.BAG1 and AAV.shROCK2 gene therapy on 
motor behavior quantified by CatWalkTM system. Results of the gait 
analysis using the CatWalkTM system displaying the mean maximum intensity 
of the foot print of the right hind limb (RHL). Means of three runs are taken for 
every animal. Bars represents the means ± SEM. AAV.EGFP, n=4; 













Activation of growth impairing pathways by inhibitory extrinsic substrates, 
scar tissue and a markedly reduced intrinsic growth capacity of adult neurons 
lead to a severely impaired axonal regeneration, sprouting and functional 
recovery after spinal cord injury (SCI). Previous studies showed that an anti-
scarring treatment applying an iron chelator 2,2'- dipyridine-5, 5’-dicarboxylic 
acid (BPY-DCA) or 8-Br-cAMP (8-bromo-cyclic adenosine monophosphate) 
to the spinal lesion could ameliorate fibrous scarring and improve axonal 
regeneration in rats (Klapka, Hermanns et al. 2005; Schiwy, Brazda et al. 
2009). Other reports have reinforced neuronal survival and axonal re-growth 
using pharmacological ROCK inhibitors and AAV-vectors over-expressing 
BAG1 and reggie1 and demonstrated that both, neuronal survival and axonal 
regeneration were improved in rat optic nerve crush lesion models (Koch et 
al., 2013; Lingor et al., 2007; Planchamp et al., 2008). The present work 
assessed the potential of a combination therapy with AAV.BAG1 and anti-
scarring treatment using BPY-DCA on axonal sprouting and motor function 
16 weeks after the dorsal spinal cord hemisection in rats. Next, the potential 
of AAV-mediated gene therapies overexpressing BAG1, reggie1 or  
miRNA-134 as well as downregulating ROCK2 (by shRNA) to promote 
restoration in a clinically relevant CNS lesion model, the dorsal spinal 
hemisection affecting the rubrospinal tract, was assessed.  
 
5.1 Effects of a combination therapy with AAV.BAG1 and AST at 16 
weeks after dorsal spinal cord hemisection 
5.1.1 Effects of anti-scarring treatment 
Scar tissue is a major barrier that impedes the growth of regeneration axons 
in the CNS and in order to facilitate axonal growth after lesion the scar tissue 
needs to be modulated to become more permissive. BPY-DCA is an iron-
chelator that inhibits prolyl-4-hydroxylase, which is a key molecule of 
collagen biosynthesis. Application of BPY-DCA in combination with 8-Br-







regeneration and motor behavior (Klapka, Hermanns et al. 2005; Schiwy, 
Brazda et al. 2009). The studies of Klapka and Schiwy used 8-Br-cAMP in 
addition to BPY-DCA where they found significant axonal regeneration and 
locomotor improvement. Since our study represented a pilot experiment, we 
only used BPY-DCA as anti-scarring treatment, which might be less effective 
compared to the BPY-DCA & 8-Br-cAMP combination. This is in line with 
previous findings, where BPY-DCA was used as single AST treatment and 
did not lead to reduced collagen scar in spinal cord lesions (Hermanns et al., 
2001). Potentially, an anti-scarring regimen with 8-Br-cAMP and BPY-DCA in 
combination with potent gene therapies might be a better combination to 
enhance axonal regeneration. 
 
5.1.2 Effects of osmotic mini-pump implantation on lesion size  
Osmotic mini-pumps were used for continuous, effective delivery of 
pharmacological agents for a defined period of time to the target tissue. This 
technique has been shown to be effective in several studies for the 
intrathecal delivery of treatment agents to the spinal cord and brain (Klapka 
et al., 2005; Kobayashi et al., 1997; Wang et al., 2006). Osmotic mini-pump 
implantation was used to deliver the anti-scarring agent BPY-DCA (or TRIS 
buffer control) to the lesioned spinal cord in rats. In our study, larger lesion 
sizes were observed in animals treated with osmotic pump implantation 
compared to the animals without pump implantation. Similarly, scar formation 
around the catheter at 16 weeks after the implantation was also observed 
suggesting a possible reason for increased lesion size following pump 
implantation. Tissue damage has been previously reported in mice with brain 
infusions using osmotic mini-pump implantation (Jabłońska et al., 1993). 
Ruetenberg et al, 2002, also reported severe tissue damage and scar 
formation with continuous outflow of the fluid from osmotic mini-pumps. In 
some cases, the long placement of the catheter in our study lead to clogging 
of the cannula leading to an improper delivery of treatment to the target 
tissue. This might also explain the ineffectiveness of the BPY-DCA treatment 
on axonal regeneration along with the bigger lesion sizes affecting the 








In spite of the limitations in animal numbers and increased lesion sizes, the 
pilot experiment suggested an increased sprouting responds for the 
AAV.BAG1-treated groups. In conclusion, the pilot trial yielded important 
information on the feasibility and limits of AAV-mediated gene therapy and 
application of AST via osmotic mini-pumps for the larger trial. Since the 
reason for pump-related lesion size increase could not be finally determined, 
we omitted this step in further experimental setups and switched to an 
adapted protocol with only AAV-mediated treatments.  
 
5.2 Optimization of anterograde RST tracing  
Anterograde tracing of the axons is a “gold standard” for assessing axonal 
regeneration in spinal cord lesion models. BDA and CTB are among the most 
commonly employed anterograde tracers for the descending spinal cord 
tracts used in many studies on spinal cord injury (Hagg et al., 2005; 
Hellenbrand et al., 2013; Reiner et al., 2000). 
 
In our paradigm, anterograde tracing with BDA could not sufficiently trace the 
RST after the lesion. Injections of AAV.dsRed into the RN, however, 
transduced the RST at least at high cervical levels. Anterograde tracing with 
RN-injections of AAV.EGFP immediately after the SC hemisection sufficiently 
labeled the RST at cervical and thoracic levels proximal to the lesion. 
 
RN neurons were reported to undergo atrophy and cell shrinkage after spinal 
cord lesions (Kwon et al., 2004; Tetzlaff et al., 1991). One explanation for the 
failure of BDA and CTB labeling could be the limited uptake of these dyes by 
atrophied RN neurons. On the other hand, the injection of AAV at the time of 
lesion was much more successful. Here, the RN neurons were not yet 
atrophied and fluorophore expression was thus not impaired.  
 
For further experiments, we thus chose the strategy of simultaneous injection 
of AAV-vectors immediately following the spinal cord lesion. That way, we 







targets of interest in a postlesional setting, mimicking the real therapeutic 
challenge present in SCI patients.  
 
5.3 Effects of gene therapy with AAV.BAG1 and AAV.reggie1, 
AAV.miRNA-134 and ROCK2.sh.RNA  
5.3.1 Toxic effects of AAV.miRNA-134 and AAV.reggie1 expression 
RNA interference (RNAi) mediated gene silencing is a powerful tool for 
knockdown of target genes. In the CNS, the blood brain barrier is a major 
limitation for systemic delivery of RNAi for chronic treatments (Meister and 
Tuschl, 2004; Scherer and Rossi, 2003). For the safe and effective delivery 
of the RNAi, AAV vectors expressing short-hairpin RNA (shRNA) or micro-
RNA (miRNA) have been employed (Hommel et al., 2003; Ulusoy et al., 
2009). In this study, we aimed to evaluate the effects of miRNA-134 on 
neuroprotection and axonal sprouting after the dorsal spinal hemisection in 
rats. Brain specific miRNA-134 expression increased dendrite spine stability 
by regulation of LIMK1 via cofilin and BDNF (Numakawa et al., 2011; Schratt 
et al., 2006). However, in the present study expression of miRNA-134 led to 
toxic effects in the RN resulting in decreased neuronal numbers. In contrast 
to paradigms, where miRNAs are expressed for a short period of time, our 
experimental model required the expression for 12 weeks. One reason for 
the observed AAV-vector toxicity could thus be the chronic expression of 
neurons to levels of miRNA-134, which are markedly higher than normal. 
This can result in a saturation of the endogenous miRNA-processing 
machinery, which could prevent other miRNA from being processed and thus 
lead to metabolic dysregulation. Another possibility could be an increased 
selective vulnerability of RN neurons. Previously, dose-mediate toxic effects 
were reported with viral-mediated RNAi in liver and brain tissue (Ehlert et al., 
2010; Grimm, 2011; Grimm et al., 2006).  
 
Unexpectedly, we observed rather pronounced toxic effects with another viral 
vector used in this study, the AAV.reggie1-vector. Reggie1 expression was 
reported to increase axonal regeneration in fish as well as in CNS (Stuermer, 







expression of reggie1 increased axonal regeneration in the optic nerve crush 
model (Koch et al., 2013). In this paradigm, AAV-mediated expression was 
used to overexpress the target protein for duration of 6 weeks and the 
targeted population was retinal ganglion cells. No obvious toxicity was 
observed in this experimental setup, which, however, was significantly 
shorter and targeted a different neuronal subtype.  
 
In conclusion, due to rather pronounced toxic effects induced by both 
AAV.miRNA-134 and AAV.reggie1 vectors, we decided to exclude these 
animals from further analysis. Excess levels of miRNA, which cannot be 
regulated with the constitutive expression from our vector system, the 
duration of target expression and the infected neuronal subtype, i.e. RN 
neurons, could all contribute to increased toxicity, which was observed in our 
study. 
 
5.3.2 Effects of AAV.BAG1 and AAV.sh.ROCK2 on RN neuronal survival 
Red nucleus neurons were reported to undergo profound cell atrophy, 
perikaryotic shrinkage and also retrograde cell death after rubrospinal tract 
injury (Kwon et al., 2004; Tetzlaff et al., 1991). However, studies on neuron-
specific application of growth factors, such as brain derived neurotropic factor 
(BDNF) also reported successful reversal of neuronal atrophy after dorsal 
hemisection (Ruitenberg et al., 2004). Since BAG1 conferred neuroprotective 
effects in models of neurovascular and neurodegenerative diseases (Jana 
and Nukina, 2005; Sroka et al., 2009), its ability to counteract lesion-induced 
neuronal atrophy was tested. The neuroprotective effects of BAG1 are known 
to be mediated not only via Hsp70, Bcl-2, Raf-1 and ERK, but also via 
inhibition of ROCK, which also a known to be neuroprotective in various 
lesion paradigms (Planchamp et al., 2008). Thus, both AAV therapies 
employed in this study were expected to beneficially affect neuronal atrophy. 
Indeed, a significant ~2-fold increase of RN neuronal counts was observed 
with neuron-specific overexpression of AAV.BAG1 and AAV.sh.ROCK2. 
AAV.BAG1 also increased the number of neurons with larger somata 







increased the number of RN neurons by ~2-fold as compared to the 
appropriate AAV.sh.firefly control, values in both shRNA-expressing vector 
groups were generally lower than in the protein-overexpressing AAV groups. 
One possible explanation for this could be the shRNA-mediated toxicity to the 
RN, possibly by overload of the intracellular miRNA-processing machinery 
(Ehlert et al., 2010).  
5.3.3 Effects of AAV.BAG1 and AAV.sh.ROCK2 on axonal sprouting and 
axonal regeneration 
While increased neuronal survival is a prerequisite for successful restoration, 
functional restitution requires the establishment of axonal projection either by 
sprouting or by regenerative growth. Collateral axonal sprouting at cervical 
level proximal to the lesion after thoracic hemisection was reported in earlier 
studies, e.g. where BDNF was applied to the cell bodies (Fouad et al., 2001; 
Vavrek et al., 2006). It represents a compensatory mechanism promoting the 
adaptive response for the recovery of motor function after SCI. Neuron-
specific overexpression of BAG1 and shRNA-mediated downregulation of 
ROCK2 significantly enhanced the axonal sprouting at both cervical and 
thoracic levels compared to their corresponding controls. Interestingly, 
AAV.sh.ROCK2-treated animals showed a 10-fold increase in sprouting 
fibres compared to the control shRNA-vector, while AAV.BAG1 improved the 
sprouting response by the factor of ~2. Disinhibition of myelin-induced growth 
impairment is a major prerequisite for an effective sprouting response 
(Tanaka et al., 2004) and AAV-mediated ROCK2-inhibition acts at exactly 
this point. Although BAG1 has been shown to regulate ROCK activity 
(Planchamp et al., 2008) this effect, in relation, seems less effective than the 
targeted downregulation of ROCK2.  
 
In contrast to the pronounced neuroprotective effects and increased cervical 
and thoracic sprouting, none of the animals showed a regeneration of EGFP-
positive axons into or even across the lesion site. True axonal regeneration 
into the lesion site depends not only on the regulation of inhibitory substrates, 
but requires a strong activation of intrinsic growth signals, e.g. as was 







BAG1 and ROCK2-inhibition enhance intrinsic growth pathways, e.g. 
MAPK/ERK (Planchamp et al., 2008). However, this alone appears 
insufficient to induce a true regenerative axonal growth and thus would call 
for combinatorial therapeutic approaches (Lingor et al., 2008).  
 
5.3.4 Effects of AAV.BAG1 and AAV.sh.ROCK2 on axonal degeneration 
and lesion size 
Stabilization of axons proximal to the lesion, e.g. by application of taxol, has 
been shown to attenuate retraction bulb formation and to promote the 
regenerative capacity of lesioned axons (Ertürk et al., 2007). Therefore, we 
assessed the potential of AAV gene therapy to stabilize RST axons. 
Although, an increase of remaining RST axons proximal to the lesion site in 
the AAV.BAG1-treated group is a common trend, the effects on axonal 
stability were marginal. In vitro, ROCK inhibition was previously shown to 
reduce axonal degeneration following lesion (Gallo, 2004) which  can be due 
to a decreased speed of microtubule depolymerization. However, this been 
effective on a short term but fails to yield sustained results in a 12-week 
lesion paradigm as in our case. Thus, the present study suggests that 
prolonged axonal stabilization requires the targeting of additional 
mechanisms, e.g. modulation of axonal autophagy (Hao et al., 2013; Kanno 
et al., 2011), which are only insufficiently addressed by AAV therapy.  
 
The lesion area per se was unaffected by whatever AAV-vector was used 
and all animals included in the study showed a continuity disruption as well 
as a cyst formation at the lesion site. This comes with no surprise, since the 
approach in the final experiment was not directed to target local scar 
formation. Unfortunately, manipulation of the lesion size by AST, as initially 
envisioned, failed due to complications of the osmotic mini-pump therapy. 
 
5.3.5 Effects of AAV.BAG1 and AAV.sh.ROCK2 on motor recovery 
Rubrospinal tract injury results in functional deficits of the limbs affecting the 
step pattern and weight bearing ability in rats (Webb and Muir, 2003), 







improvement of the animals with the BBB open field test. To increase the 
sensitivity, specific parameters such as trunk instability, toe clearance and 
paw placement were assessed as sub score. In correlation to the most 
pronounced improvement in neuronal survival and collateral sprouting, a 
significant improvement in the sub score was observed in the AAV.BAG1 
treated group. AAV.sh.ROCK2-treated animals showed a trend for motor 
improvement, but didn’t reach statistical significance and this correlated with 
less important improvements in the histological parameters in this treatment 
group.  
 
5.4 Conclusion and perspectives 
Regeneration and functional restoration after spinal cord injury (SCI) largely 
depends on neuroprotection and the targeting of inhibitory pathways. In order 
to restore SC function, it is thus crucial to simultaneously attenuate inhibitory 
signaling and promote neuroprotection. Here, we investigated AAV-mediated 
gene therapy with various strategies: over-expression of BAG1, reggie1, and 
miRNA-134 and downregulation of ROCK2 via shRNA. All of these molecular 
targets aim at the increase of neuronal survival and/or disinhibition of key 
inhibitory pathways for axonal growth. Our studies clearly demonstrate that 
not only the choice of the target molecule, but also its AAV-vector-mediated 
expression itself can have a significant influence on the biological outcome. 
 
Due to the complexity of SC injury pathophysiology it is very likely that 
combinational studies with synergistic effects will be used in future 
approaches. For example, combination treatments with neurotrophic factors, 
chondroitinase ABC (a bacterial enzyme degrading CSPGs), cell therapies 
and molecules interacting with inhibitory pathways gained much attention in 
recent years. For example, Pearse et.al showed that a combination of cAMP 
and Schwann cells promote axonal regeneration and motor function recovery 
after spinal cord lesion in rats in (Pearse et al., 2004). A combination of 
Nogo-A antibody and chondroitinase ABC also showed effects on functional 
recovery and this was more pronounced than the single treatment (Zhao et 
al., 2013). Targeting pathways other than Rho-ROCK, such semaphorins, 







Recently, robust axonal regeneration and sprouting was obtained by 
modulating the PTEN/mTOR pathway after spinal cord injury in mice (Liu et 
al., 2010). Taken together, combination therapies could be important to 
achieve more pronounced beneficial effects after the spinal cord injury and 
our study yields two interesting targets, which are worthwhile to be explored 
in such therapies: BAG1 and ROCK2. 
 
6 Summary and conclusions 
 
The rat rubrospinal tract lesion is an established model for traumatic spinal 
cord injury, which results in atrophy of the red nucleus neurons, axonal 
dieback and locomotor deficits.  
 
1. In the pilot experiment, a combination of AAV.BAG1 and BPY-DCA anti-
scarring treatment in a rat model of unilateral dorsal spinal cord lesion 
was tested. Animals were followed up for 16 weeks. A trend to increased 
sprouting was observed in the AAV.BAG1-treated animals, but there was 
no significant functional improvement by the treatment. On the contrary, 
we observed increased lesion sizes after implantation of osmotic mini-
pumps in the spinal cord. 
2. Anterograde tracing experiments with BDA and CTB suggested that the 
atrophied RN neurons were unable to take up the dye after the lesion 
and injections of AAV-vectors immediately after SCI were more effective 
for the labelling of the RST. 
3. In the final experiment, AAV gene therapy was used to overexpress 
BAG1, reggie1, miRNA-134 and ROCK2-shRNA in the red nucleus in 
order to trace (by co-expression of EGFP) and treat the rubrospinal tract 
after unilateral dorsal hemisection. Toxic effects were observed by 
expression of AAV.miRNA-134 and AAV.reggie1. However, expression 
of BAG1 and ROCK2-shRNA promoted neuronal survival of red nucleus 
neurons and enhanced axonal sprouting proximal to the lesion. Only 








Taken together, this study implies that AAV-mediated gene therapy is a 
highly interesting future therapeutic tool for the treatment of traumatic CNS 
injuries. BAG1 represents a valuable target, stimulating neuronal survival and 
collateral sprouting. Although BAG1 expression is able to down-regulate 
ROCK activity, additional pathways likely mediate its beneficial effects in the 
present model, since ROCK2 down-regulation alone was less powerful. 
Interestingly, shRNA-mediated down-regulation of ROCK2 appears to have a 
stronger effect on axonal sprouting, which could be explained by only partial 
ROCK2 inhibition following BAG1 overexpression. Future studies will have to 
address the value of both targets in combination treatments, which should 









Anderson, C.R., Ashwell, K.W., Collewijn, H., Conta, A., Harvey, A., Heise, 
C., Hodgetts, S., Holstege, G., Kayalioglu, G., Keast, J.R., et al. (2009). The 
Spinal Cord: A Christopher and Dana Reeve Foundation Text and Atlas. In 
The Spinal Cord, C. Watson, G. Paxinos, and G. Kayalioglu, eds. (San 
Diego: Academic Press), p. v. 
Arber, S., Barbayannis, F.A., Hanser, H., Schneider, C., Stanyon, C.A., 
Bernard, O., and Caroni, P. (1998). Regulation of actin dynamics through 
phosphorylation of cofilin by LIM-kinase. Nature 393, 805–809. 
Azzouz, M., Hottinger, A., Paterna, J.C., Zurn, A.D., Aebischer, P., and 
Büeler, H. (2000). Increased motoneuron survival and improved 
neuromuscular function in transgenic ALS mice after intraspinal injection of 
an adeno-associated virus encoding Bcl-2. Hum. Mol. Genet. 9, 803–811. 
Basso, D.M., Beattie, M.S., and Bresnahan, J.C. (1995). A sensitive and 
reliable locomotor rating scale for open field testing in rats. J. Neurotrauma 
12, 1–21. 
Benson, M.D., Romero, M.I., Lush, M.E., Lu, Q.R., Henkemeyer, M., and 
Parada, L.F. (2005). Ephrin-B3 is a myelin-based inhibitor of neurite 
outgrowth. Proc. Natl. Acad. Sci. U. S. A. 102, 10694–10699. 
Bickel, P.E., Scherer, P.E., Schnitzer, J.E., Oh, P., Lisanti, M.P., and Lodish, 
H.F. (1997). Flotillin and Epidermal Surface Antigen Define a New Family of 
Caveolae-associated Integral Membrane Proteins. J. Biol. Chem. 272, 
13793–13802. 
Blits, B., Oudega, M., Boer, G.J., Bartlett Bunge, M., and Verhaagen, J. 
(2003). Adeno-associated viral vector-mediated neurotrophin gene transfer in 
the injured adult rat spinal cord improves hind-limb function. Neuroscience 
118, 271–281. 
Blits, B., Carlstedt, T.P., Ruitenberg, M.J., de Winter, F., Hermens, 
W.T.J.M.C., Dijkhuizen, P.A., Claasens, J.W.C., Eggers, R., van der Sluis, 
R., Tenenbaum, L., et al. (2004). Rescue and sprouting of motoneurons 
following ventral root avulsion and reimplantation combined with intraspinal 
adeno-associated viral vector-mediated expression of glial cell line-derived 
neurotrophic factor or brain-derived neurotrophic factor. Exp. Neurol. 189, 
303–316. 
Blits, B., Derks, S., Twisk, J., Ehlert, E., Prins, J., and Verhaagen, J. (2010). 
Adeno-associated viral vector (AAV)-mediated gene transfer in the red 
nucleus of the adult rat brain: comparative analysis of the transduction 
properties of seven AAV serotypes and lentiviral vectors. J. Neurosci. 
Methods 185, 257–263. 








Buchli, A.D., and Schwab, M.E. (2005). Inhibition of Nogo: a key strategy to 
increase regeneration, plasticity and functional recovery of the lesioned 
central nervous system. Ann. Med. 37, 556–567. 
Buller, R.M., Janik, J.E., Sebring, E.D., and Rose, J.A. (1981). Herpes 
simplex virus types 1 and 2 completely help adenovirus-associated virus 
replication. J. Virol. 40, 241–247. 
Bunge, R.P., Puckett, W.R., Becerra, J.L., Marcillo, A., and Quencer, R.M. 
(1993). Observations on the pathology of human spinal cord injury. A review 
and classification of 22 new cases with details from a case of chronic cord 
compression with extensive focal demyelination. Adv. Neurol. 59, 75–89. 
Carter, L.M., McMahon, S.B., and Bradbury, E.J. (2011). Delayed treatment 
with chondroitinase ABC reverses chronic atrophy of rubrospinal neurons 
following spinal cord injury. Exp. Neurol. 228, 149–156. 
Coleman, M.P., and Perry, V.H. (2002). Axon pathology in neurological 
disease: a neglected therapeutic target. Trends Neurosci. 25, 532–537. 
Crowe, M.J., Bresnahan, J.C., Shuman, S.L., Masters, J.N., and Crowe, M.S. 
(1997). Apoptosis and delayed degeneration after spinal cord injury in rats 
and monkeys. Nat. Med. 3, 73–76. 
Daya, S., and Berns, K.I. (2008). Gene Therapy Using Adeno-Associated 
Virus Vectors. Clin. Microbiol. Rev. 21, 583–593. 
Dergham, P., Ellezam, B., Essagian, C., Avedissian, H., Lubell, W.D., and 
McKerracher, L. (2002). Rho signaling pathway targeted to promote spinal 
cord repair. J. Neurosci. Off. J. Soc. Neurosci. 22, 6570–6577. 
Donnelly, D.J., and Popovich, P.G. (2008). Inflammation and its role in 
neuroprotection, axonal regeneration and functional recovery after spinal 
cord injury. Exp. Neurol. 209, 378–388. 
Doucette, T.A., Ryan, C.L., and Tasker, R.A. (2000). Use of osmotic 
minipumps for sustained drug delivery in rat pups: effects on physical and 
neurobehavioural development. Physiol. Behav. 71, 207–212. 
Ehlers, M.D. (2004). Deconstructing the axon: Wallerian degeneration and 
the ubiquitin-proteasome system. Trends Neurosci. 27, 3–6. 
Ehlert, E.M., Eggers, R., Niclou, S.P., and Verhaagen, J. (2010). Cellular 
toxicity following application of adeno-associated viral vector-mediated RNA 
interference in the nervous system. BMC Neurosci. 11, 20. 
Emery, E., Aldana, P., Bunge, M.B., Puckett, W., Srinivasan, A., Keane, 
R.W., Bethea, J., and Levi, A.D. (1998). Apoptosis after traumatic human 
spinal cord injury. J. Neurosurg. 89, 911–920. 
Ertürk, A., Hellal, F., Enes, J., and Bradke, F. (2007). Disorganized 
microtubules underlie the formation of retraction bulbs and the failure of 







Fawcett, J.W., Housden, E., Smith-Thomas, L., and Meyer, R.L. (1989). The 
growth of axons in three-dimensional astrocyte cultures. Dev. Biol. 135, 449–
458. 
Fehlings, M.G., Theodore, N., Harrop, J., Maurais, G., Kuntz, C., Shaffrey, 
C.I., Kwon, B.K., Chapman, J., Yee, A., Tighe, A., et al. (2011). A phase I/IIa 
clinical trial of a recombinant Rho protein antagonist in acute spinal cord 
injury. J. Neurotrauma 28, 787–796. 
Filli, L., and Schwab, M.E. (2012). The rocky road to translation in spinal cord 
repair. Ann. Neurol. 72, 491–501. 
Forgione, N., and Fehlings, M.G. (2013). Rho-ROCK Inhibition in the 
Treatment of Spinal Cord Injury. World Neurosurg. 
Fouad, K., Pedersen, V., Schwab, M.E., and Brösamle, C. (2001). Cervical 
sprouting of corticospinal fibers after thoracic spinal cord injury accompanies 
shifts in evoked motor responses. Curr. Biol. 11, 1766–1770. 
Frisén, J., Fried, K., Sjögren, A.M., and Risling, M. (1993). Growth of 
ascending spinal axons in CNS scar tissue. Int. J. Dev. Neurosci. Off. J. Int. 
Soc. Dev. Neurosci. 11, 461–475. 
Gage, G.J., Kipke, D.R., and Shain, W. (2012). Whole Animal Perfusion 
Fixation for Rodents. J. Vis. Exp. JoVE. 
Gallo, G. (2004). Myosin II activity is required for severing-induced axon 
retraction in vitro. Exp. Neurol. 189, 112–121. 
García-Alías, G., Lin, R., Akrimi, S.F., Story, D., Bradbury, E.J., and Fawcett, 
J.W. (2008). Therapeutic time window for the application of chondroitinase 
ABC after spinal cord injury. Exp. Neurol. 210, 331–338. 
Geffner, L.F., Santacruz, P., Izurieta, M., Flor, L., Maldonado, B., Auad, A.H., 
Montenegro, X., Gonzalez, R., and Silva, F. (2008). Administration of 
Autologous Bone Marrow Stem Cells Into Spinal Cord Injury Patients Via 
Multiple Routes Is Safe and Improves Their Quality of Life: Comprehensive 
Case Studies. Cell Transplant. 17, 1277–1293. 
Gemma, M., Perego, G.B., Pizzini, G., and Tredici, G. (1987). Distribution of 
the cortico-spinal fibres in the cervical and lumbar enlargements of the rat 
spinal cord. J. Für Hirnforsch. 28, 457–462. 
Giger, R.J., Hollis, E.R., 2nd, and Tuszynski, M.H. (2010). Guidance 
molecules in axon regeneration. Cold Spring Harb. Perspect. Biol. 2, 
a001867. 
Goldshmit, Y., Galea, M.P., Wise, G., Bartlett, P.F., and Turnley, A.M. (2004). 
Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. J. 
Neurosci. Off. J. Soc. Neurosci. 24, 10064–10073. 
Götz, R., Wiese, S., Takayama, S., Camarero, G.C., Rossoll, W., Schweizer, 







is essential for differentiation and survival of hematopoietic and neuronal 
cells. Nat. Neurosci. 8, 1169–1178. 
Grimm, D. (2011). The dose can make the poison: lessons learned from 
adverse in vivo toxicities caused by RNAi overexpression. Silence 2, 8. 
Grimm, D., Streetz, K.L., Jopling, C.L., Storm, T.A., Pandey, K., Davis, C.R., 
Marion, P., Salazar, F., and Kay, M.A. (2006). Fatality in mice due to 
oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 
537–541. 
Guest, J., Santamaria, A.J., and Benavides, F.D. (2013). Clinical translation 
of autologous Schwann cell transplantation for the treatment of spinal cord 
injury. Curr. Opin. Organ Transplant. 18, 682–689. 
Hagg, T., and Oudega, M. (2006). Degenerative and Spontaneous 
Regenerative Processes after Spinal Cord Injury. J. Neurotrauma 23, 263–
280. 
Hagg, T., Baker, K.A., Emsley, J.G., and Tetzlaff, W. (2005). Prolonged local 
neurotrophin-3 infusion reduces ipsilateral collateral sprouting of spared 
corticospinal axons in adult rats. Neuroscience 130, 875–887. 
Hamers, F.P., Lankhorst, A.J., van Laar, T.J., Veldhuis, W.B., and Gispen, 
W.H. (2001). Automated quantitative gait analysis during overground 
locomotion in the rat: its application to spinal cord contusion and transection 
injuries. J. Neurotrauma 18, 187–201. 
Hao, H.-H., Wang, L., Guo, Z.-J., Bai, L., Zhang, R.-P., Shuang, W.-B., Jia, 
Y.-J., Wang, J., Li, X.-Y., and Liu, Q. (2013). Valproic acid reduces 
autophagy and promotes functional recovery after spinal cord injury in rats. 
Neurosci. Bull. 29, 484–492. 
Hashimoto, R., Nakamura, Y., Kosako, H., Amano, M., Kaibuchi, K., Inagaki, 
M., and Takeda, M. (1999). Distribution of Rho-kinase in the bovine brain. 
Biochem. Biophys. Res. Commun. 263, 575–579. 
Hayes, K.C., Davies, A.L., Ashki, N., Kramer, J.K., and Close, T.E. (2007). 
Re: Ditunno JF, Little JW, Tessler A, Burns AS. Spinal shock revisited: a 
four-phase model. Spinal Cord 2004; 42: 383-395. Spinal Cord 45, 395–396. 
Hellal, F., Hurtado, A., Ruschel, J., Flynn, K.C., Laskowski, C.J., Umlauf, M., 
Kapitein, L.C., Strikis, D., Lemmon, V., Bixby, J., et al. (2011). Microtubule 
stabilization reduces scarring and causes axon regeneration after spinal cord 
injury. Science 331, 928–931. 
Hellenbrand, D.J., Kaeppler, K.E., Hwang, E., Ehlers, M.E., Toigo, R.D., 
Giesler, J.D., Vassar-Olsen, E.R., and Hanna, A. (2013). Basic techniques 
for long distance axon tracing in the spinal cord. Microsc. Res. Tech. 76, 
1240–1249. 
Hendriks, W.T.J., Eggers, R., Ruitenberg, M.J., Blits, B., Hamers, F.P.T., 







long-term functional recovery after defined spinal tract lesions in the rat. J. 
Neurotrauma 23, 18–35. 
Hermanns, S., Reiprich, P., and Müller, H.W. (2001). A reliable method to 
reduce collagen scar formation in the lesioned rat spinal cord. J. Neurosci. 
Methods 110, 141–146. 
Hill, C.E., Beattie, M.S., and Bresnahan, J.C. (2001). Degeneration and 
sprouting of identified descending supraspinal axons after contusive spinal 
cord injury in the rat. Exp. Neurol. 171, 153–169. 
Hommel, J.D., Sears, R.M., Georgescu, D., Simmons, D.L., and DiLeone, 
R.J. (2003). Local gene knockdown in the brain using viral-mediated RNA 
interference. Nat. Med. 9, 1539–1544. 
Jabłońska, B., Gierdalski, M., Kublik, A., Skangiel-Kramska, J., and Kossut, 
M. (1993). Effects of implantation of Alzet 1007D osmotic minipumps upon 2-
deoxyglucose uptake in the cerebral cortex of mice. Acta Neurobiol. Exp. 
(Warsz.) 53, 577–580. 
James W. Rowland, Gregory W. J. Hawryluk, Brian Kwon, and Michael G. 
Fehlings (2008). Current status of acute spinal cord injury pathophysiology 
and emerging therapies: promise on the horizon. 
Jana, N.R., and Nukina, N. (2005). BAG-1 associates with the polyglutamine-
expanded huntingtin aggregates. Neurosci. Lett. 378, 171–175. 
Kanno, H., Ozawa, H., Sekiguchi, A., Yamaya, S., and Itoi, E. (2011). 
Induction of autophagy and autophagic cell death in damaged neural tissue 
after acute spinal cord injury in mice. Spine 36, E1427–1434. 
Kaplitt, M.G., Leone, P., Samulski, R.J., Xiao, X., Pfaff, D.W., O’Malley, K.L., 
and During, M.J. (1994). Long-term gene expression and phenotypic 
correction using adeno-associated virus vectors in the mammalian brain. Nat. 
Genet. 8, 148–154. 
Kastin, A.J., and Pan, W. (2005). Targeting neurite growth inhibitors to 
induce CNS regeneration. Curr. Pharm. Des. 11, 1247–1253. 
Kermer, P., Krajewska, M., Zapata, J.M., Takayama, S., Mai, J., Krajewski, 
S., and Reed, J.C. (2002). Bag1 is a regulator and marker of neuronal 
differentiation. Cell Death Differ. 9, 405–413. 
Kerschensteiner, M., Schwab, M.E., Lichtman, J.W., and Misgeld, T. (2005). 
In vivo imaging of axonal degeneration and regeneration in the injured spinal 
cord. Nat. Med. 11, 572–577. 
Kiyota, T., Yamamoto, M., Schroder, B., Jacobsen, M.T., Swan, R.J., 
Lambert, M.P., Klein, W.L., Gendelman, H.E., Ransohoff, R.M., and Ikezu, T. 
(2009). AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 
mutant suppresses gliosis, beta-amyloidosis, and learning impairment of 







Klapka, N., Hermanns, S., Straten, G., Masanneck, C., Duis, S., Hamers, 
F.P.T., Müller, D., Zuschratter, W., and Müller, H.W. (2005). Suppression of 
fibrous scarring in spinal cord injury of rat promotes long-distance 
regeneration of corticospinal tract axons, rescue of primary motoneurons in 
somatosensory cortex and significant functional recovery. Eur. J. Neurosci. 
22, 3047–3058. 
Knoller, N., Auerbach, G., Fulga, V., Zelig, G., Attias, J., Bakimer, R., Marder, 
J.B., Yoles, E., Belkin, M., Schwartz, M., et al. (2005). Clinical experience 
using incubated autologous macrophages as a treatment for complete spinal 
cord injury: phase I study results. J. Neurosurg. Spine 3, 173–181. 
Kobayashi, N.R., Fan, D.P., Giehl, K.M., Bedard, A.M., Wiegand, S.J., and 
Tetzlaff, W. (1997). BDNF and NT-4/5 prevent atrophy of rat rubrospinal 
neurons after cervical axotomy, stimulate GAP-43 and Talpha1-tubulin 
mRNA expression, and promote axonal regeneration. J. Neurosci. Off. J. 
Soc. Neurosci. 17, 9583–9595. 
Koch, J.C., Barski, E., Lingor, P., Bähr, M., and Michel, U. (2011). Plasmids 
containing NRSE/RE1 sites enhance neurite outgrowth of retinal ganglion 
cells via sequestration of REST independent of NRSE dsRNA expression. 
FEBS J. 278, 3472–3483. 
Koch, J.C., Solis, G.P., Bodrikov, V., Michel, U., Haralampieva, D., 
Shypitsyna, A., Tönges, L., Bähr, M., Lingor, P., and Stuermer, C.A.O. 
(2013). Upregulation of reggie-1/flotillin-2 promotes axon regeneration in the 
rat optic nerve in vivo and neurite growth in vitro. Neurobiol. Dis. 51, 168–
176. 
Koda, M., Hashimoto, M., Murakami, M., Yoshinaga, K., Ikeda, O., Yamazaki, 
M., Koshizuka, S., Kamada, T., Moriya, H., Shirasawa, H., et al. (2004). 
Adenovirus vector-mediated in vivo gene transfer of brain-derived 
neurotrophic factor (BDNF) promotes rubrospinal axonal regeneration and 
functional recovery after complete transection of the adult rat spinal cord. J. 
Neurotrauma 21, 329–337. 
Komagome, R., Kimura, K., and Saito, M. (2000). Postnatal changes in Rho 
and Rho-related proteins in the mouse brain. Jpn. J. Vet. Res. 47, 127–133. 
Küchler, M., Fouad, K., Weinmann, O., Schwab, M.E., and Raineteau, O. 
(2002). Red nucleus projections to distinct motor neuron pools in the rat 
spinal cord. J. Comp. Neurol. 448, 349–359. 
Kügler, S., Meyn, L., Holzmüller, H., Gerhardt, E., Isenmann, S., Schulz, J.B., 
and Bähr, M. (2001). Neuron-specific expression of therapeutic proteins: 
evaluation of different cellular promoters in recombinant adenoviral vectors. 
Mol. Cell. Neurosci. 17, 78–96. 
Kundi (2013). SPINAL CORD INJURY: CURRENT MAMMALIAN MODELS. 







Kwon, B.K., Liu, J., Messerer, C., Kobayashi, N.R., McGraw, J., Oschipok, L., 
and Tetzlaff, W. (2002a). Survival and regeneration of rubrospinal neurons 1 
year after spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 99, 3246–3251. 
Kwon, B.K., Liu, J., Oschipok, L., and Tetzlaff, W. (2002b). Reaxotomy of 
Chronically Injured Rubrospinal Neurons Results in Only Modest Cell Loss. 
Exp. Neurol. 177, 332–337. 
Kwon, B.K., Liu, J., Oschipok, L., Teh, J., Liu, Z.W., and Tetzlaff, W. (2004). 
Rubrospinal neurons fail to respond to brain-derived neurotrophic factor 
applied to the spinal cord injury site 2 months after cervical axotomy. Exp. 
Neurol. 189, 45–57. 
Kwon, B.K., Liu, J., Lam, C., Plunet, W., Oschipok, L.W., Hauswirth, W., Di 
Polo, A., Blesch, A., and Tetzlaff, W. (2007). Brain-derived neurotrophic 
factor gene transfer with adeno-associated viral and lentiviral vectors 
prevents rubrospinal neuronal atrophy and stimulates regeneration-
associated gene expression after acute cervical spinal cord injury. Spine 32, 
1164–1173. 
Langhorst, M.F., Jaeger, F.A., Mueller, S., Sven Hartmann, L., Luxenhofer, 
G., and Stuermer, C.A.O. (2008). Reggies/flotillins regulate cytoskeletal 
remodeling during neuronal differentiation via CAP/ponsin and Rho 
GTPases. Eur. J. Cell Biol. 87, 921–931. 
Lehmann, M., Fournier, A., Selles-Navarro, I., Dergham, P., Sebok, A., 
Leclerc, N., Tigyi, G., and McKerracher, L. (1999). Inactivation of Rho 
signaling pathway promotes CNS axon regeneration. J. Neurosci. Off. J. Soc. 
Neurosci. 19, 7537–7547. 
Lingor, P., Teusch, N., Schwarz, K., Mueller, R., Mack, H., Bähr, M., and 
Mueller, B.K. (2007). Inhibition of Rho kinase (ROCK) increases neurite 
outgrowth on chondroitin sulphate proteoglycan in vitro and axonal 
regeneration in the adult optic nerve in vivo. J. Neurochem. 103, 181–189. 
Lingor, P., Tönges, L., Pieper, N., Bermel, C., Barski, E., Planchamp, V., and 
Bähr, M. (2008). ROCK inhibition and CNTF interact on intrinsic signalling 
pathways and differentially regulate survival and regeneration in retinal 
ganglion cells. Brain J. Neurol. 131, 250–263. 
Liu, K., Lu, Y., Lee, J.K., Samara, R., Willenberg, R., Sears-Kraxberger, I., 
Tedeschi, A., Park, K.K., Jin, D., Cai, B., et al. (2010). PTEN deletion 
enhances the regenerative ability of adult corticospinal neurons. Nat. 
Neurosci. 13, 1075–1081. 
Liu, Y., Kim, D., Himes, B.T., Chow, S.Y., Schallert, T., Murray, M., Tessler, 
A., and Fischer, I. (1999). Transplants of fibroblasts genetically modified to 
express BDNF promote regeneration of adult rat rubrospinal axons and 








Mackay-Sim, A., Féron, F., Cochrane, J., Bassingthwaighte, L., Bayliss, C., 
Davies, W., Fronek, P., Gray, C., Kerr, G., Licina, P., et al. (2008). 
Autologous olfactory ensheathing cell transplantation in human paraplegia: a 
3-year clinical trial. Brain J. Neurol. 131, 2376–2386. 
Mandel, R.J., Spratt, S.K., Snyder, R.O., and Leff, S.E. (1997). Midbrain 
injection of recombinant adeno-associated virus encoding rat glial cell line-
derived neurotrophic factor protects nigral neurons in a progressive 6-
hydroxydopamine-induced degeneration model of Parkinson’s disease in 
rats. Proc. Natl. Acad. Sci. U. S. A. 94, 14083–14088. 
Matsui, T., Amano, M., Yamamoto, T., Chihara, K., Nakafuku, M., Ito, M., 
Nakano, T., Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996). Rho-
associated kinase, a novel serine/threonine kinase, as a putative target for 
small GTP binding protein Rho. EMBO J. 15, 2208–2216. 
Mautes, A.E., Weinzierl, M.R., Donovan, F., and Noble, L.J. (2000). Vascular 
Events After Spinal Cord Injury: Contribution to Secondary Pathogenesis. 
Phys. Ther. 80, 673–687. 
McCown, T.J. (2005). Adeno-associated virus (AAV) vectors in the CNS. 
Curr. Gene Ther. 5, 333–338. 
McCown, T.J., Xiao, X., Li, J., Breese, G.R., and Samulski, R.J. (1996). 
Differential and persistent expression patterns of CNS gene transfer by an 
adeno-associated virus (AAV) vector. Brain Res. 713, 99–107. 
McKerracher, L. (2001). Spinal cord repair: strategies to promote axon 
regeneration. Neurobiol. Dis. 8, 11–18. 
De Medinaceli, L. (1986). An anatomical landmark for procedures on rat 
thoracic spinal cord. Exp. Neurol. 91, 404–408. 
Meijering, E., Jacob, M., Sarria, J.-C.F., Steiner, P., Hirling, H., and Unser, M. 
(2004). Design and validation of a tool for neurite tracing and analysis in 
fluorescence microscopy images. Cytom. Part J. Int. Soc. Anal. Cytol. 58, 
167–176. 
Meister, G., and Tuschl, T. (2004). Mechanisms of gene silencing by double-
stranded RNA. Nature 431, 343–349. 
Metz, G.A., and Whishaw, I.Q. (2002). Cortical and subcortical lesions impair 
skilled walking in the ladder rung walking test: a new task to evaluate fore- 
and hindlimb stepping, placing, and co-ordination. J. Neurosci. Methods 115, 
169–179. 
Metz, G.A., and Whishaw, I.Q. (2009). The ladder rung walking task: a 
scoring system and its practical application. J. Vis. Exp. JoVE. 
Michel, U., Malik, I., Ebert, S., Bähr, M., and Kügler, S. (2005). Long-term in 
vivo and in vitro AAV-2-mediated RNA interference in rat retinal ganglion 








Mueller, B.K., Mack, H., and Teusch, N. (2005). Rho kinase, a promising 
drug target for neurological disorders. Nat. Rev. Drug Discov. 4, 387–398. 
Munderloh, C., Solis, G.P., Bodrikov, V., Jaeger, F.A., Wiechers, M., Málaga-
Trillo, E., and Stuermer, C.A.O. (2009). Reggies/Flotillins Regulate Retinal 
Axon Regeneration in the Zebrafish Optic Nerve and Differentiation of 
Hippocampal and N2a Neurons. J. Neurosci. 29, 6607–6615. 
Nakagawa, O., Fujisawa, K., Ishizaki, T., Saito, Y., Nakao, K., and Narumiya, 
S. (1996). ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil 
forming protein serine/threonine kinase in mice. FEBS Lett. 392, 189–193. 
Norenberg, M.D., Smith, J., and Marcillo, A. (2004). The pathology of human 
spinal cord injury: defining the problems. J. Neurotrauma 21, 429–440. 
Numakawa, T., Richards, M., Adachi, N., Kishi, S., Kunugi, H., and Hashido, 
K. (2011). MicroRNA function and neurotrophin BDNF. Neurochem. Int. 59, 
551–558. 
Ohashi, K., Nagata, K., Maekawa, M., Ishizaki, T., Narumiya, S., and Mizuno, 
K. (2000). Rho-associated Kinase ROCK Activates LIM-kinase 1 by 
Phosphorylation at Threonine 508 within the Activation Loop. J. Biol. Chem. 
275, 3577–3582. 
Paxinos, G., and Watson, C. (1998). The Rat Brain: In Stereotaxic 
Coordinates (Academic Press, Incorporated). 
Paxinos, G., Watson, C., Pennisi, M., and Topple, A. (1985). Bregma, 
lambda and the interaural midpoint in stereotaxic surgery with rats of different 
sex, strain and weight. J. Neurosci. Methods 13, 139–143. 
Pearse, D.D., Pereira, F.C., Marcillo, A.E., Bates, M.L., Berrocal, Y.A., Filbin, 
M.T., and Bunge, M.B. (2004). cAMP and Schwann cells promote axonal 
growth and functional recovery after spinal cord injury. Nat. Med. 10, 610–
616. 
Peel, A.L., and Klein, R.L. (2000). Adeno-associated virus vectors: activity 
and applications in the CNS. J. Neurosci. Methods 98, 95–104. 
Planchamp, V., Bermel, C., Tönges, L., Ostendorf, T., Kügler, S., Reed, J.C., 
Kermer, P., Bähr, M., and Lingor, P. (2008). BAG1 promotes axonal 
outgrowth and regeneration in vivo via Raf-1 and reduction of ROCK activity. 
Brain J. Neurol. 131, 2606–2619. 
Rahimi-Movaghar, V. Saturated Picric Acid Prevents Autophagia and Self-
Mutilation in Laboratory Rats. 
Reiner, A., Veenman, C.L., Medina, L., Jiao, Y., Del Mar, N., and Honig, M.G. 
(2000). Pathway tracing using biotinylated dextran amines. J. Neurosci. 
Methods 103, 23–37. 
Ren, K., Gao, C., Zhang, J., Wang, K., Xu, Y., Wang, S.-B., Wang, H., Tian, 







the cultured cells during Cu2+ stimulation through molecular interaction. Mol. 
Neurobiol. 48, 631–646. 
Rolls, A., Shechter, R., and Schwartz, M. (2009). The bright side of the glial 
scar in CNS repair. Nat. Rev. Neurosci. 10, 235–241. 
Rossignol, S., Schwab, M., Schwartz, M., and Fehlings, M.G. (2007). Spinal 
cord injury: time to move? J. Neurosci. Off. J. Soc. Neurosci. 27, 11782–
11792. 
Rowland, J.W., Hawryluk, G.W.J., Kwon, B., and Fehlings, M.G. (2008). 
Current status of acute spinal cord injury pathophysiology and emerging 
therapies: promise on the horizon. Neurosurg. Focus 25, E2. 
Ruitenberg, M.J., Eggers, R., Boer, G.J., and Verhaagen, J. (2002). Adeno-
associated viral vectors as agents for gene delivery: application in disorders 
and trauma of the central nervous system. Methods San Diego Calif 28, 182–
194. 
Ruitenberg, M.J., Blits, B., Dijkhuizen, P.A., te Beek, E.T., Bakker, A., van 
Heerikhuize, J.J., Pool, C.W., Hermens, W.T.J., Boer, G.J., and Verhaagen, 
J. (2004). Adeno-associated viral vector-mediated gene transfer of brain-
derived neurotrophic factor reverses atrophy of rubrospinal neurons following 
both acute and chronic spinal cord injury. Neurobiol. Dis. 15, 394–406. 
Samuel, F., and Hynds, D.L. (2010). RHO GTPase Signaling for Axon 
Extension: Is Prenylation Important? Mol. Neurobiol. 42, 133–142. 
Santiago, J.M., Torrado, A.I., Arocho, L.C., Rosas, O.R., Rodríguez, A.E., 
Toro, F.K., Salgado, I.K., Torres, Y.A., Silva, W.I., and Miranda, J.D. (2013). 
Expression profile of flotillin-2 and its pathophysiological role after spinal cord 
injury. J. Mol. Neurosci. MN 49, 347–359. 
Scherer, L.J., and Rossi, J.J. (2003). Approaches for the sequence-specific 
knockdown of mRNA. Nat. Biotechnol. 21, 1457–1465. 
Schiwy, N.E. (2010). Axonale Regeneration und Plastizität unterschiedlicher 
Fasersysteme nach Rückenmarksverletzungen und verschiedenen 
Behandlungsansätzen in der adulten Ratte. 
Schiwy, N., Brazda, N., and Müller, H.W. (2009). Enhanced regenerative 
axon growth of multiple fibre populations in traumatic spinal cord injury 
following scar-suppressing treatment. Eur. J. Neurosci. 30, 1544–1553. 
Schnell, L., Fearn, S., Schwab, M.E., Perry, V.H., and Anthony, D.C. (1999). 
Cytokine-induced acute inflammation in the brain and spinal cord. J. 
Neuropathol. Exp. Neurol. 58, 245–254. 
Schratt, G.M., Tuebing, F., Nigh, E.A., Kane, C.G., Sabatini, M.E., Kiebler, 
M., and Greenberg, M.E. (2006). A brain-specific microRNA regulates 







Schrock, Y., Solis, G.P., and Stuermer, C.A.O. (2009). Regulation of focal 
adhesion formation and filopodia extension by the cellular prion protein 
(PrPC). FEBS Lett. 583, 389–393. 
Schulte, T., Paschke, K.A., Laessing, U., Lottspeich, F., and Stuermer, C.A. 
(1997). Reggie-1 and reggie-2, two cell surface proteins expressed by retinal 
ganglion cells during axon regeneration. Dev. Camb. Engl. 124, 577–587. 
Schwab, M.E. (1996). Structural plasticity of the adult CNS. Negative control 
by neurite growth inhibitory signals. Int. J. Dev. Neurosci. Off. J. Int. Soc. 
Dev. Neurosci. 14, 379–385. 
Schwartz, E.D., Cooper, E.T., Chin, C.-L., Wehrli, S., Tessler, A., and 
Hackney, D.B. (2005). Ex vivo Evaluation of ADC Values within Spinal Cord 
White Matter Tracts. Am. J. Neuroradiol. 26, 390–397. 
Shearer, M.C., and Fawcett, J.W. (2001). The astrocyte/meningeal cell 
interface--a barrier to successful nerve regeneration? Cell Tissue Res. 305, 
267–273. 
Silva, N.A., Sousa, N., Reis, R.L., and Salgado, A.J. (2014). From basics to 
clinical: A comprehensive review on spinal cord injury. Prog. Neurobiol. 114, 
25–57. 
Solis, G.P., Schrock, Y., Hulsbusch, N., Wiechers, M., Plattner, H., and 
Stuermer, C.A.O. (2012). Reggies/flotillins regulate E-cadherin-mediated cell 
contact formation by affecting EGFR trafficking. Mol. Biol. Cell 23, 1812–
1825. 
Song, J., Takeda, M., and Morimoto, R.I. (2001). Bag1-Hsp70 mediates a 
physiological stress signalling pathway that regulates Raf-1/ERK and cell 
growth. Nat. Cell Biol. 3, 276–282. 
Sroka, K., Voigt, A., Deeg, S., Reed, J.C., Schulz, J.B., Bähr, M., and 
Kermer, P. (2009). BAG1 modulates huntingtin toxicity, aggregation, 
degradation, and subcellular distribution. J. Neurochem. 111, 801–807. 
Starkey, M.L., Bartus, K., Barritt, A.W., and Bradbury, E.J. (2012). 
Chondroitinase ABC promotes compensatory sprouting of the intact 
corticospinal tract and recovery of forelimb function following unilateral 
pyramidotomy in adult mice. Eur. J. Neurosci. 36, 3665–3678. 
Steward, O., Zheng, B., and Tessier-Lavigne, M. (2003). False resurrections: 
distinguishing regenerated from spared axons in the injured central nervous 
system. J. Comp. Neurol. 459, 1–8. 
Stichel, C.C., and Müller, H.W. (1994). Relationship between injury-induced 
astrogliosis, laminin expression and axonal sprouting in the adult rat brain. J. 
Neurocytol. 23, 615–630. 
Stichel, C.C., Hermanns, S., Luhmann, H.J., Lausberg, F., Niermann, H., 







collagen IV deposition promotes regeneration of injured CNS axons. Eur. J. 
Neurosci. 11, 632–646. 
Stuermer, C.A.O. (2010). The reggie/flotillin connection to growth. Trends 
Cell Biol. 20, 6–13. 
Sun, F., Park, K.K., Belin, S., Wang, D., Lu, T., Chen, G., Zhang, K., Yeung, 
C., Feng, G., Yankner, B.A., et al. (2011). Sustained axon regeneration 
induced by co-deletion of PTEN and SOCS3. Nature 480, 372–375. 
Takayama, S., Sato, T., Krajewski, S., Kochel, K., Irie, S., Milian, J.A., and 
Reed, J.C. (1995). Cloning and functional analysis of BAG-1: A novel Bcl-2-
binding protein with anti-cell death activity. Cell 80, 279–284. 
Tanaka, H., Yamashita, T., Yachi, K., Fujiwara, T., Yoshikawa, H., and 
Tohyama, M. (2004). Cytoplasmic p21(Cip1/WAF1) enhances axonal 
regeneration and functional recovery after spinal cord injury in rats. 
Neuroscience 127, 155–164. 
Tator, C.H., and Fehlings, M.G. (1991). Review of the secondary injury 
theory of acute spinal cord trauma with emphasis on vascular mechanisms. 
J. Neurosurg. 75, 15–26. 
Tator, C.H., and Koyanagi, I. (1997). Vascular mechanisms in the 
pathophysiology of human spinal cord injury. J. Neurosurg. 86, 483–492. 
Taymans, J.-M., Vandenberghe, L.H., Haute, C.V.D., Thiry, I., Deroose, 
C.M., Mortelmans, L., Wilson, J.M., Debyser, Z., and Baekelandt, V. (2007). 
Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, 
and 8 in mouse brain. Hum. Gene Ther. 18, 195–206. 
Tester, N.J., and Howland, D.R. (2008). Chondroitinase ABC improves basic 
and skilled locomotion in spinal cord injured cats. Exp. Neurol. 209, 483–496. 
Tetzlaff, W., Alexander, S.W., Miller, F.D., and Bisby, M.A. (1991). Response 
of facial and rubrospinal neurons to axotomy: changes in mRNA expression 
for cytoskeletal proteins and GAP-43. J. Neurosci. Off. J. Soc. Neurosci. 11, 
2528–2544. 
Thuret, S., Moon, L.D.F., and Gage, F.H. (2006). Therapeutic interventions 
after spinal cord injury. Nat. Rev. Neurosci. 7, 628–643. 
Tönges, L., Koch, J.-C., Bähr, M., and Lingor, P. (2011). ROCKing 
Regeneration: Rho Kinase Inhibition as Molecular Target for 
Neurorestoration. Front. Mol. Neurosci. 4, 39. 
Tönges, L., Frank, T., Tatenhorst, L., Saal, K.A., Koch, J.C., Szego, É.M., 
Bähr, M., Weishaupt, J.H., and Lingor, P. (2012). Inhibition of rho kinase 
enhances survival of dopaminergic neurons and attenuates axonal loss in a 
mouse model of Parkinson’s disease. Brain J. Neurol. 135, 3355–3370. 
Tönges, L., Günther, R., Suhr, M., Jansen, J., Balck, A., Saal, K.-A., Barski, 







modulates microglia activation and improves survival in a model of 
amyotrophic lateral sclerosis. Glia 62, 217–232. 
Tseng, G.F., Wang, Y.J., and Hu, M.E. (1996). Axotomy affects the 
retrograde labeling of cervical and lumbar-cord-projecting rubrospinal 
neurons differently. Anat. Embryol. (Berl.) 194, 457–464. 
Ulusoy, A., Sahin, G., Björklund, T., Aebischer, P., and Kirik, D. (2009). Dose 
Optimization for Long-term rAAV-mediated RNA Interference in the 
Nigrostriatal Projection Neurons. Mol. Ther. 17, 1574–1584. 
Vavrek, R., Girgis, J., Tetzlaff, W., Hiebert, G.W., and Fouad, K. (2006). 
BDNF promotes connections of corticospinal neurons onto spared 
descending interneurons in spinal cord injured rats. Brain 129, 1534–1545. 
Verma, R.K., Arora, S., and Garg, S. (2004). Osmotic pumps in drug delivery. 
Crit. Rev. Ther. Drug Carrier Syst. 21, 477–520. 
Wang, J.T., Medress, Z.A., and Barres, B.A. (2012). Axon degeneration: 
Molecular mechanisms of a self-destruction pathway. J. Cell Biol. 196, 7–18. 
Wang, X., Baughman, K.W., Basso, D.M., and Strittmatter, S.M. (2006). 
Delayed Nogo Receptor Therapy Improves Recovery from Spinal Cord 
Contusion. Ann. Neurol. 60, 540–549. 
Watzlawick, R., Sena, E.S., Dirnagl, U., Brommer, B., Kopp, M.A., Macleod, 
M.R., Howells, D.W., and Schwab, J.M. (2013). Effect and Reporting Bias of 
RhoA/ROCK-Blockade Intervention on Locomotor Recovery After Spinal 
Cord Injury: A Systematic Review and Meta-analysis. JAMA Neurol. 
Webb, A.A., and Muir, G.D. (2003). Unilateral dorsal column and rubrospinal 
tract injuries affect overground locomotion in the unrestrained rat. Eur. J. 
Neurosci. 18, 412–422. 
Weidner, N., Ner, A., Salimi, N., and Tuszynski, M.H. (2001). Spontaneous 
corticospinal axonal plasticity and functional recovery after adult central 
nervous system injury. Proc. Natl. Acad. Sci. U. S. A. 98, 3513–3518. 
Wiessner, C., Bareyre, F.M., Allegrini, P.R., Mir, A.K., Frentzel, S., Zurini, M., 
Schnell, L., Oertle, T., and Schwab, M.E. (2003). Anti-Nogo-A antibody 
infusion 24 hours after experimental stroke improved behavioral outcome and 
corticospinal plasticity in normotensive and spontaneously hypertensive rats. 
J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 23, 
154–165. 
Wu, B., Bi, Z., and Qi, Q. (2013). Inactivation of the Rho-ROCK signaling 
pathway to promote neurologic recovery after spinal cord injuries in rats. 
Chin. Med. J. (Engl.) 126, 3723–3727. 
Wu, D., Yang, P., Zhang, X., Luo, J., Haque, M.E., Yeh, J., Richardson, P.M., 
Zhang, Y., and Bo, X. (2009). Targeting a dominant negative rho kinase to 
neurons promotes axonal outgrowth and partial functional recovery after rat 







Wu, Z., Asokan, A., and Samulski, R.J. (2006). Adeno-associated virus 
serotypes: vector toolkit for human gene therapy. Mol. Ther. J. Am. Soc. 
Gene Ther. 14, 316–327. 
Yezierski, R.P. (1996). Pain following spinal cord injury: the clinical problem 
and experimental studies. Pain 68, 185–194. 
Yiu, G., and He, Z. (2006). Glial inhibition of CNS axon regeneration. Nat. 
Rev. Neurosci. 7, 617–627. 
Zhang, X., Wang, H., Zhang, S., Song, J., Zhang, Y., Wei, X., and Feng, Z. 
(2012). MiR-134 functions as a regulator of cell proliferation, apoptosis, and 
migration involving lung septation. In Vitro Cell. Dev. Biol. Anim. 48, 131–
136. 
Zhang, Y.P., Onifer, S.M., Burke, D.A., and Shields, C.B. (2001). A topical 
mixture for preventing, abolishing, and treating autophagia and self-mutilation 
in laboratory rats. Contemp. Top. Lab. Anim. Sci. Am. Assoc. Lab. Anim. Sci. 
40, 35–36. 
Zhao, R.-R., Andrews, M.R., Wang, D., Warren, P., Gullo, M., Schnell, L., 
Schwab, M.E., and Fawcett, J.W. (2013). Combination treatment with anti-
Nogo-A and chondroitinase ABC is more effective than single treatments at 
enhancing functional recovery after spinal cord injury. Eur. J. Neurosci. 38, 
2946–2961. 
Zolotukhin, I., Luo, D., Gorbatyuk, O., Hoffman, B., Warrington, K., Jr, 
Herzog, R., Harrison, J., and Cao, O. (2013). Improved Adeno-associated 
Viral Gene Transfer to Murine Glioma. J. Genet. Syndr. Gene Ther. 4. 
Zolotukhin S et al. (1999). Recombinant adeno-associated virus purification 
using novel methods improves infectious titer and yield. Publ. Online 03 June 











List of Abbreviations 
 
~                              approximately 
1x, 2x, 3x                1 time, 2 times, 3 times 
μm                           micrometer 
AP   anterior-posterior  
AAD                         acute axonal degeneration 
AAV   adeno associated virus  
ABC   avidin-biotin-complex  
ASB                         antiscaring buffer treatment 
AST   antiscaring treatment  
ATP   adenosine triphosphate 
BAG1   Bcl-2-associated athanogene-1  
BBB   locomotor test/scale (developed by Basso, Beattie and 
Bresnahan)  
BDA   biotinylated dextran amine  
BDNF             brain derived neurotrophic factors  
BPY-DCA  2,2`- bipyridine-5,5`-dicarboxylic acid (iron chelator)  
CaCl2   calcium chloride  
cAMP   cycloadenosine monophosphate 
CNS    central nervous system  
CSF    cerebrospinal fluid  
CSPG   chondroitin sulfate proteoglycan  
CST    corticospinal tract  
CTB                         cholera toxin B 
CX                           cortex 
DAPI    4‘,6-Diamidino-2-phenylindole  
DNA   deoxyribonucleic acid 
DsRed  Discosoma red fluorescent protein  
DV                           dorsoventral 
ECM    extracellular matrix 







Egf-R   epidermal growth factor receptor 
EGFP   enhanced green fluorescent protein 
ETOH   ethanol  
GFAP   glial fibrillary acidic protein 
g   grams 
H2O2   hydrogen peroxide  
HCl    hydrochloric acid  
hr.                            hour 
hrs.                          hours 
LHL    left hind limb  
MAG    myelin-associated glycoprotein 
n                              number 
NOGO            myelin-associated inhibitors  
MAPK   mitogen-activated protein kinase 
ML                           mediolateral 
miRNA                    micro RNA 
mm                          millimeter 
Na+   sodium  
NaCl    sodium chloride  
NaOH   sodium hydroxide solution  
NgR    NOGO receptor  
NO2   nitrous oxide  
NSCs   neural stem cells 
O2   oxygen  
OMGp   oligodendrocyte myelin glycoprotein 
OMN                        occulo motor nerve fibers 
PBS    phosphate buffered saline  
PCR   polymerase chain reaction 
PFA    paraformaldehyde  
PNS    peripheral nervous system  
RHL   right hind limb  
RN    red nucleus 
RNA   ribonucleic acid 







rpm   rounds per minute  
RST    rubrospinal tract  
RT   room temperature  
SC    spinal cord  
SCI    spinal cord injury 
shRNA  short hairpin RNA 
SN                           substantia nigra 
Th   thoracic level  
TRIS             TRIS(hydroxymethyl)-aminomethane  
TU   transducing units 
v/v    volume per volume  
vh    ventral horn  
vWF    von Willebrand factor, endothelial marker  












Vector maps of AAV.miRNA-134 and AAV.reggie1. Schematic depiction of 
vector maps of (a) AAV.miRNA-134, (b) AAV.reggie1. Restriction sites used 
for cloning were showed on the external side of the map. ITR, inverted 
terminal repeats; hSyn, human synapsin 1 gene promoter; Int, intron; SV40, 
simian virus 40 polyadenylation site; EGFP, enhanced green fluorescent 













Vector maps of AAV.EGFP and AAV.BAG1 flag. Schematic depiction of 
vector maps of (a) AAV.EGFP, (b) AAV.BAG1 flag. Restriction sites used for 
cloning were showed on the external side of the map. ITR, inverted terminal 
repeats; hSyn, human synapsin 1 gene promoter; Int, intron; SV40, simian 
virus 40 polyadenylation site; EGFP, enhanced green fluorescent protein 



















Vector maps of AAV.sh.firefly and AAV.sh.ROCK2. Schematic depiction 
of vector maps of (a) AAV.sh.firefly  (b) AAV.sh.ROCK2,  Restriction sites 
used for cloning were showed on the external side of the map. ITR, inverted 
terminal repeats; hSyn, human synapsin 1 gene promoter; Int, intron; SV40, 
simian virus 40 polyadenylation site; EGFP, enhanced green fluorescent 
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